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This thesis is focused on understanding the biochemical mechanisms of 
engineering of the deoxyxylulose phosphate (DXP) pathway for the overproduction of 
isoprenoids. 
 
Overexpression of rate limiting DXP enzymes has been the most effective 
method in biochemical pathway engineering for the overproduction of isoprenoids. 
Expression levels of the overexpressed enzymes had to be balanced; otherwise isoprenoid 
productivity was found to be significantly inhibited. In this thesis, the hypothesis that 
transcription of isoprenoid synthetic genes were altered during protein overexpression 
which resulted in the inhibition of production was tested.  In order to pursue this 
hypothesis, it was necessary to accurately quantify gene transcriptions in the engineered 
E. coli. The commonly used references genes, rrsA and ihfB, for data normalization, were 
found to be highly unreliable. Thus, the search for more reliable genes useful for 
normalization of transcriptional studies by meta-analysis of various databases was 
initiated, which identified 20 putative transcripts. Of these, idnT, cysG and hcaT, were 
found to serve as reliable reference genes for protein overexpression conditions. Using 
these normalizers, the isoprenoid production inhibition was found not to be due to the 
changes in transcriptions of isoprenoid synthetic genes. The usefulness of the 
transcription quantification method established in this study extends beyond the scope of 
this study. 
 





Next, we aimed to establish quantification method for the metabolites in the DXP 
pathway because this could provide accurate and direct information on the activities of 
the pathway enzymes and the identification of possible regulatory structures. By virtue of 
the strong acidity of the DXP metabolites (all are phosphorylated compounds), an anion-
exchange solid phase extraction (SPE) method was exploited for high-throughput and 
rapid enrichment from cell extracts. All the metabolites were readily detected by liquid 
chromatography mass spectrometry (LC-MS) after the SPE purification with high 
recoveries. With the established method, the DXP metabolite MEC was unexpectedly 
found to be accumulated inside the cells and actively effluxed into the media by a yet to 
be understood mechanism. The efflux of MEC diverted a large portion of carbon flux 
away from isoprenoid biosynthesis and possibly contributed to the observed decrease in 
isoprenoid production. The enzyme utilizing MEC, ispG, was then overexpressed to 
reduce the efflux, which successfully increased isoprenoid production. This study 
developed invaluable tools for the understanding and engineering of the DXP metabolism.  
 
With the established analytical tools in this thesis, solubility and activity of the 
overexpressed DXP enzymes were systematically examined. Experimentations in three E. 
coli expression systems confirmed that dxs, ispG, ispH and ispA were highly insoluble 
(solubility less than 30%). It was validated that the insoluble dxs, the committed enzyme 
in the DXP pathway, was almost completely void of catalytic activity. The solubility and 
activity of this enzyme was significantly improved by the use of an osmolyte (sorbitol), 
resulting in enhanced production of isoprenoid precursor DXP. The data in this chapter 
highlighted an overlooked issue in engineering of the DXP pathway – protein solubility, 
and developed a novel strategy based on this to enhance overproduction of isoprenoids.  
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Chapter 1: Introduction  
1 INTRODUCTION 
 
1.1 BACKGROUND AND OBJECTIVES 
 
Isoprenoids are a large family of compounds (more than 55,000) comprising 
numerous products used as fragrances, insecticides, nutraceuticals and pharmaceuticals [1, 
2]. These valuable compounds and their chemically convertible precursors are extracted 
from plant based resources that contain only low level of the metabolites (less than 1% 
biomass) [3]. The plant resources are regenerated at  a very slow rate (at least in months), 
and the supply based on them is highly variable, mainly caused by weather conditions 
and volatile market demand of isoprenoids [3]. It also raises environmental concerns, for 
example, Himalayan yew tree was recently deemed as an endangered species due to over 
medicinal use according to IUCN1 red list. Hence, it is a challenge to meet the increasing 
market demand of many isoprenoid products, such as artemisinin (anti-malaria drug) [4] 
and paclitaxel (anti-cancer drug) [5]. So far, it is still not possible to chemically 
synthesize most isoprenoids economically from simple building blocks, mainly because 
of their structural complexities [5]. To meet this challenge, plant cell fermentation (PCF) 
has been developed, where plant cells were isolated and propagated in suspension culture 
for production purpose [3, 6]. Bristol-Myers Squibb, the largest paclitaxel supplier in the 
world, has recently licensed PCF technology from Phyton Biotech and aimed to replace 
their current supply of paclitaxel from yew trees. However, this technology to date still 
                                                     
1 IUCN: International Union for Conservation of Nature 
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faced the problem of variable productivity, mainly due to cell line degradation by yet to 
be understood mechanisms [6]. 
 
By virtue of advances in recombinant protein technology, now it is possible to 
genetically modify metabolism of fast growing microbes and graft heterologous pathways 
to the microbes, so that they can be used to produce high value natural products from 
economical carbon sources (e.g. glucose, xylose and glycerol etc.) [2, 7]. Based on this 
concept, comprehensive studies have been done, aiming to economically and sustainably 
produce isoprenoids in microbes by metabolic engineering [5, 8-11]. Thus far, a number 
of isoprenoid products and their precursors, such as taxadiene [5], artemisinic acid [7], 
lycopene [12] and levopimaridiene [13], have been successfully produced in the model 
microorganism Escherichia coli (E. coli) at levels in the  grams per liter titer. To do so, 
genes were cloned from host plants and recombinantly expressed in E. coli to 
functionalize an isoprenoid template molecule farnesyl diphosphate (FPP), which is a 
native metabolite and synthesized by deoxyxylulose phosphate (DXP) pathway (also 
known as MEP pathway) [14]. Various strategies were further exploited in enhancing the 
productivity of isoprenoids in E. coli, including overexpression of rate-limiting enzymes 
[10], knock-out of competing pathways [15] and combinatorial approaches such as global 
transcription machinery engineering (gTME) [16]. Despite the progress with the current 
methods, majority of the engineering approaches are still combinatorial in nature, where 
the underlying biochemical mechanisms are poorly understood [17]. Studies have shown 
that a variety of experimental conditions were found to have negative impacts on 
isoprenoid productions [9, 10, 12] and the reasons for these were yet to be unraveled.  
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This thesis attempts to understand the biochemical mechanisms underlying the 
production of isoprenoids by engineering the endogenous DXP pathway. In the process, a 
set of novel genes were identified and used for the normalization of gene expression to 
determine accurate transcription changes in the E. coli with engineered DXP pathway. 
The conclusion from the study was that lycopene (an isoprenoid) production inhibition 
with gene over-expression was not due to altered transcription of genes in the pathway. In 
addition, for the first time, a quantitative LC-MS method was developed for the 
simultaneous quantification of all DXP metabolites enabling the direct monitoring of 
changes in engineered cells. It was unknown until this study that many of the over-
expressed endogenous DXP enzymes formed inclusion bodies, limiting their usefulness. 
Attempts were made to increase the solubility of some of these enzymes which resulted 
in enhanced isoprenoid production in E. coli. Thus, the quantitative methods developed 
and the identification of critical issues has major impact on the field of Metabolic 
Engineering and far beyond the scope of this study. Besides, this study also developed 
essential and useful molecular tools for isoprenoid production in generally regarded as 
safe (GRAS) strain Bacillus subtilis (B. subtilis), a strain more suitable for microbial 









































Figure 1.1 The deoxyxylulose phosphate (DXP) pathway 
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In the DXP pathway, pyruvate (PYR) and glyceraldehyde 3-phosphate (GAP) are first condensed by dxs with 
thiamine to produce 1-deoxy-D-xylulose 5-phosphate (DXP) [14]. DXP is then reduced and isomerized by a 
single enzyme, dxr, with NADPH to form 2C-methyl-D-erythritol 4-phosphate (MEP) [14]. MEP reacts with 
CTP in the presence of ispD to produce 4-diphosphocytidyl-2C-methyl D-erythritol (CDP-ME) [14]. CDP-
ME is phosphorylated by an ATP dependent kinase ispE to form 4-diphosphocytidyl-2C-methyl D-erythritol 
2-phosphate (CDP-MEP) [14]. CMP is eliminated from CDP-MEP and the molecule is cyclized by ispF to 
form 2C-methyl-D-erythritol 2,4-diphosphate (MEC) [14]. The ring structure of MEC is opened and reduced 
by an iron-sulfur cluster containing enzyme ispG by a yet to be fully characterized mechanism to form 
hydroxylmethylbutenyl diphosphate (HMBPP) [18]. HMBPP is further reduced by another iron-sulfur cluster 
containing enzyme ispH to produce a mixture of isopentenyl diphosphate (IPP) and dimethylallyl 
diphosphate (DMAPP) [19]. 
 
1.2 LITERATURE REVIEW 
 
1.2.1 Isoprenoid biosynthesis 
 
Despite highly diverse structures, all the isoprenoids are derived from 
isopentensyl diphosphate (IPP) and dimethylallyl diphosphate (DMAPP) [14], which are 
synthesized by either the DXP pathway (Figure 1.1) or the mevalonate pathway in nature. 
The mevalonate pathway exists in most eukaryotes (all mammals), archaea, a few 
eubacteria, the cytosol and mitochondria of plants and fungi [14]. The enzymes involved 
in the DXP pathway were only fully identified recently, and this pathway exists in plant 
chloroplasts, algae, cyanobacteria, eubacteria and apicomplexan parasites [14]. Recently, 
the complete mevalonate pathway was expressed heterologously in E. coli to supply IPP 
and DMAPP along with the endogenous DXP pathway [4, 20]. The engineering was 
effective in boosting isoprenoid productivity, but it required the simultaneous expression 
of six heterologous enzymes, where under some circumstances resulted in the disruption 
of E. coli fatty acid biosynthesis [21]. On the other hand, the use of the endogenous DXP 
pathway alone, requiring less genetic modification and no heterologous gene expression, 
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was found to be equally efficient in producing isoprenoid in E. coli [5, 11]. During the 
development of the DXP pathway for isoprenoid production, researchers were confronted 
with the following questions: What are the enzymes in the DXP pathway? Is there a way 
to manipulate the DXP pathway enzymes and which ones are rate limiting to isoprenoid 
biosynthesis and thus needed to be manipulated? What are the optimal expression levels 
of the rate-limiting DXP enzymes for isoprenoid production and why isoprenoid 
production is low when expression levels of the DXP enzymes are not optimized? The 
solutions and attempts to answer these questions were discussed below in greater detail.  
 
1.2.2 The DXP pathway enzymes 
 
1.2.2.1 Dxs and dxr 
 
DXP is the first metabolic intermediate in the DXP pathway for isoprenoid 
biosynthesis, and it is also an essential precursor for biosynthesis of vitamin B6, a vital 
co-enzyme in E. coli amino acid metabolism [22]. It is condensed by the enzyme dxs 
from D-glyceraldehyde 3-phosphate (GAP) and pyruvate (PYR) [23]. Thiamine 
diphosphate is required as essential co-factor, and the carboxyl group of pyruvate was 
cleaved and released as CO2 (Figure 1.2). As the committed enzyme in the DXP pathway, 
dxs has been demonstrated to be rate-limiting for production of isoprenoid products in a 
variety of organisms, including gram negative bacteria [10], gram positive bacteria [24] 
and plants [25]. In presence of NADPH, DXP was reduced and rearranged by the enzyme 
dxr into MEP, the compound that was well accepted to be used only for biosynthesis of 
isoprenoids [26]. Hence, the DXP pathway was also known as the MEP pathway when it 




Chapter 1: Introduction  
was employed for overproduction of isoprenoid compounds [5]. A few reports showed 
that it was not rate-limiting to isoprenoid biosynthesis in E. coli [10, 27]. Fosmidomycin, 
a structural analogue of MEP, has been discovered to be a potent antibiotic compound 
[28], which inhibits dxr from various species including malaria parasite plasmodium [29]. 
The first two enzymes, dxs and dxr, form the upper DXP pathway and drain carbon 



















Figure 1.2 The reaction catalyzed by dxs [23] 
PYR: pyruvate, GAP: glyceraldehyde 3-phosphate, DXP: 1-deoxy-D-xylulose 5-phosphate, TPP: thiamine 

















Figure 1.3 The reaction catalyzed by dxr [26] 
DXP: 1-deoxy-D-xylulose 5-phosphate, MEP: 2-C-methyl-D-erythritol 4-phosphate, dxr: 1-deoxy-D-
xylulose 5-phosphate reductase 
 
1.2.2.2 IspD, ispE and ispF 
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To synthesize isoprenoids, the phosphate group of MEP needs to be activated by 
the enzyme ispD with CTP, which formed CDP-ME [30]. Thy hydroxyl group on C2 
position of CDP-ME is further activated by ATP phosphorylation in the presence of the 
enzyme ispE [31]. The product CDP-MEP is intramolecularly cyclized into MEC by the 
enzyme ispF with the release of a CMP [32] (Figure 1.4). In E. coli ispD and ispF genes 
are co-regulated in one transcriptional operon [27], and in some other species (such as 
Campylobacter jejuni) the two genes are fused encoding a bifunctional enzyme [31]. This 
is unusual because ispD and ispF catalyze non-consecutive steps of the DXP pathway. 
Further biochemical studies revealed that 6 ispDF enzymes could dedicatedly assemble 
with 6 the intervening enzyme ispE to form one protein complex, colocalizing the 18 
active sites for efficient conversion of MEP into MEC [31]. The three enzymes, ispD, 
ispE and ispF, constitute the core of the DXP pathway for isoprenoid biosynthesis, and 



























Figure 1.4 The reaction catalyzed by ispD, ispE and ispF [31] 
MEP: 2-C-methyl-D-erythritol 4-phosphate, CDP-ME: 4-diphosphocytidyl-2C-methyl D-erythritol, CDP-
MEP: 4-diphosphocytidyl-2C-methyl D-erythritol 2-phosphate, MEC: 2C-methyl-D-erythritol 2,4-
diphosphate, ispD: 4-diphosphocytidyl-2C-methyl-D-erythritol synthase, ispE: 4-diphosphocytidyl-2-C-
methylerythritol kinase, ispF: 2C-methyl-D-erythritol 2,4-cyclodiphosphate synthase 
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1.2.2.3 IspG and ispH 
 
The ring structure of MEC is opened by binding to the iron-sulfur cluster ([4Fe-
4S]2-) embedded in the enzyme ispG. In presence of reduction systems (e.g. NADPH-
flavodoxin reductase), the organometallic metabolic intermediate is deoxygenated at C3 
position to form HMBPP (Figure 1.5). Similarly, HMBPP also forms organometallic 
metabolic intermediates with the aid of the enzyme ispH and deoxygenated to DMAPP 
and IPP (molar ratio of approximately 1:5) (Figure 1.6). The mechanisms of ispG and 
ispH reaction have drawn enormous attentions from biochemists, because such 
deoxygenation reaction is difficult to accomplish by using conventional organic 
chemistry approaches. So far, many details in the mechanisms are still under debate [33, 
34]. The enzymes ispG and ispH form the downstream of the DXP pathway to produce 
the IPP and DMAPP, and they were found not to be rate-limiting to the biosynthesis of 
isoprenoids. However, this thesis demonstrated that a large portion of carbon flux was 
diverted by the cells away from isoprenoid production at the point of the enzyme ispG, 
highlighting the importance of these two enzymes that were significantly underestimated 





























Figure 1.5 The reaction catalyzed by ispG [33] 




















IPP DMAPP  
Figure 1.6 The reaction catalyzed by ispH [34] 
 
1.2.3 Enzyme overexpression  
 
Enzymes are proteins that catalyze biotransformation of metabolites inside the 
cells, and intracellular metabolic fluxes are largely determined by the abundance of the 
enzymes in vivo [35-37]. Enzymes can be overexpressed by genetic engineering 
constitutively or in a controllable manner so as to increase fluxes through desired 
pathways in E. coli [5, 20]. The controllable enzyme expression systems allow induction 
of transcription or translation at a specific cell growth stage, minimizing stresses on the 
host cells [38]. In E. coli, discovery of the lac operon and understanding of its regulatory 
principles in 1960s laid foundation for the modern controllable enzyme expression 
systems [39]. Later, by combining the lac control system with stronger promoters 
identified in bacteriophage (e.g. T7 (Figure 1.7) and T5 etc.) [40, 41], the use of the non-
metabolizable inducer IPTG [42] has provided a unique expression system with wide 
dynamic range in the control of transcription. To date, the lac based expression systems 
and those that uses other sugars as inducers (e.g. arabinose [10] and xylose [43] etc.) have 
been widely employed in manipulation of E. coli for isoprenoid production. For example, 
the first committed enzyme of the DXP pathway, dxs, was overexpressed using the lac 
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promoter [8] or the araBAD promoter [10], for the production of  high levels of lycopene 
(an isoprenoid) in E. coli.  
 
 
Figure 1.7 Illustration of regulation of T7 promoter system in E. coli [44] 
A most commonly used T7 promoter system for E. coli is illustrated here to demonstrate modern regulatable 
promoter systems. Gene expression by T7 promoter requires available T7 RNA polymerase and lack of LacI 
repressor on the lac operator. Availability of T7 RNA polymerase is under control of lac promoter, which i 
also blocked by lacI repressor in the default condition. Addition of IPTG released lacI repressor from both lac 
and T7 promoter, and T7 RNA polymerase is produced to initiate gene expression by the T7 promoter.  PT7: 
T7 promoter; LacO: lac operator; RBS: ribosome binding sites; Gene: target gene to express, LacI: lacI 
repressor; Plac: lac promoter; T7RP: T7 RNA polymerase 
 
1.2.4 Overexpression of the enzymes in the DXP pathway 
 
Due to constraints in gene cloning technologies [45] and the stresses caused by 
recombinant enzyme over-expressions [46], the number of enzymes used is kept to be 
minimal. Only those enzymes controlling critical pathway flux are often over-expressed, 
e.g. rate-limiting enzymes. Dxs, the committed enzyme in the DXP pathway, was readily 
identified to be rate-limiting after its discovery, as the overexpression of dxs resulted in 
significant increases in lycopene production [8, 10]. The next enzyme in the DXP 
pathway, dxr, was also investigated in a similar way, but its expression did not 
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significantly enhance lycopene production [10]. Dxr was then considered not to be a rate-
limiting enzyme in the pathway. By virtue of reddish color of lycopene, Yuan et al. [27] 
systematically screened all the genes in the DXP pathway plus idi and ispA for 
isoprenoid production, where a mixture of the integration plasmids individually 
expressing the DXP genes were transformed with a lycopene producing E. coli, and the 
high producer strain was picked and sequenced. The identified rate-limiting gene was 
then integrated into genome of the E. coli, and the new round screening using the easily 
identifiable isoprenoid, lycopene, was carried which led to the discovery of idi and ispDF 
as critical genes (Figure 1.8). Since then, the simultaneous overexpression of dxs, idi and 
ispDF was widely used to enhance isoprenoid production in E. coli [5, 11].  
 
Identification of the optimal expression levels of these rate-limiting DXP 
enzymes (dxs-idi-ispDF) was a challenging task, given that a wide range of their 
expression levels needed to be examined and the expression levels of downstream 
isoprenoid synthases also had to be controlled simultaneously for maximal production of 
the isoprenoids. For example, optimal expression levels of dxs-idi-ispDF was only 
identified in a taxadiene producing strain, after testing a large number of combinations of 
expression levels of the dxs-idi-ispDF operon and the ggpps-tds operon, encoding the 
taxadiene synthase (Figure 1.9) [5]. Completion of the comprehensive expression 
optimization for the DXP genes dxs-idi-ispDF required enormous numbers of plasmid 
constructions and strain development.    
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Figure 1.8 Combinatorial identification of the rate-limiting DXP enzymes [27] 
 
 
Figure 1.9 Empirical optimization of expression levels of rate limiting DXP enzymes [5]  
 
1.2.5 Why controlling the enzyme expression levels are important? 
 
As an important step towards rational engineering of microbial isoprenoid 
production, Ajikumar et al. [5] explored the reason why expression levels of dxs-idi-
ispDF and ggpps-tds need to be dedicatedly controlled to achieve maximal taxadiene 
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production. Indole, an E. coli signal molecule, was discovered to be inversely correlated 
with the taxadiene production [5]. Though the molecular mechanism relating taxadiene 
production and indole production was unknown, it was speculated that indole inhibited 
taxadiene synthesis and indole production was repressed when expression levels of dxs-
idi-ispDF and ggpps-tds were well tuned. Prior to the study, it had been frequently 
observed that isoprenoid production was increased when the DXP enzymes were 
moderately overexpressed (with weak promoters [8] or non-induced strong promoters 
[10]) while the production was severely repressed when the enzymes were strongly 
overexpressed [9, 10]. It was proposed that the DXP pathway could divert too much GAP 
and pyruvate, important glycolytic intermediates, to isoprenoid production which might 
disturb the entire cellular metabolism [10]. The large number of co-factors consumed in 
isoprenoid production (1 lycopene requires 16 NADPH, 8 ATP and 8 CTP) was also 
believed to be a reason for the inhibitory effects caused by strong overexpression of the 
DXP enzymes [12]. However, none of the above hypotheses had been systematically 
investigated at the start of this thesis, which could be due to the lack of quantitative tools 
for measuring the changes of the DXP pathway in transcription and metabolite levels. 
 
1.2.6 A common yet weak assumption in the use of enzyme overexpression in 
metabolic engineering 
 
In all the prior arts of engineering of the DXP pathway for overproduction of 
isoprenoid products, there was a generally and tacitly accepted assumption that increasing 
the overexpression of recombinant DXP enzymes shows an equivalent increase in 
catalytic activities. This is unlikely to be true especially when the enzymes are strongly 
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overexpressed, where the use of the cellular protein folding machinery may be saturated 
and a significant fraction of enzymes may not be properly folded and hence, not fully 
functional [47]. The presence of incorrectly folded enzymes and unpredictable catalytic 
activities then limit accurate mathematical reconstruction of the pathway in silico for the 
purpose of optimizing the isoprenoid production. This issue of protein insolubility has 
been intensively studied in the field of recombinant protein production, and many 
effective solutions have been proposed such as lowering growth temperature, changing 
host strains and using fusion partners and chaperones etc [47]. However, insolubility of 
the recombinant enzymes has not yet been systematically investigated in metabolic 
engineering of microbes for isoprenoid production. 
 
1.2.7 Effective strategies for enhancing microbial isoprenoid production other 
than enzyme overexpression 
 
1.2.7.1 Genetic knockout of competing pathways 
 
Elimination of the enzymes related to the target pathway may channel more flux 
towards the pathway [48]. To determine the most effective targets of gene knockout for 
increasing the flux through the DXP pathway, the entire E. coli central metabolism was 
reconstructed in silico [48], where the consequences of each gene knockout can be 
predicted. A panel of knockout candidates was identified by the in silico simulations 
(Figure 1.10 A, [48]), which were individually validated for production of lycopene 
(Figure 1.10 B, [48]). The single knockout that yielded the best lycopene productivity 
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was then set as the background in the next round single knockout screening. The iteration 





Figure 1.10 Gene knockout for enhancing the DXP pathway flux [48] 
(A) talB, gpmAB, aceE, fdhF and gdhA were predicted knockout candidates; (B) experiment validation 
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1.2.7.2 Global transcription machinery engineering (gTME) 
 
Combinatorial engineering approaches can complement rational genetic 
modification methods, because multiple distinct genes can be simultaneously modified by 
combinatorial engineering [17]. Due to the large number of mutants generated by 
combinatorial engineering, it is only useful when these mutants can be screened for better 
phenotype in a high throughput manner.  The isoprenoid lycopene has strong absorption 
at 470nm, and therefore its cellular concentration can be easily determined when the cells 
grow into colonies on agar plates, allowing rapid screening of high lycopene producers 
[11]. By taking advantage of this feature, high lycopene producers were selected from a 
library of E. coli whose transcriptome was disturbed by overexpression of mutated sigma 
factor 70 (Figure 1.11, [16]). Reverse engineering of gTME still lacks to date, which 
would be very valuable because effective rational approaches can be designed after 
understanding of the improved mutants in molecular level. 
 
 
Figure 1.11 Global transcription machinery engineering for lycopene production [16] 
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1.2.7.3 Fermentation technology 
 
Optimization of fermentation is a traditional strategy in biotechnology and has 
been proved to be effective for improving microbial isoprenoid productivity [49]. It was 
found that the C15 isoprenoid amorphadiene could be air-stripped during fermentation, 
resulting significant loss of the products [49]. A two-phase fermentation was then 
developed to overcome this problem, where dodecane was applied as an overlay organic 
layer to trap amorphadiene (Figure 1.12 [49]). This strategy was also found to be 
applicable to fermentation for taxadiene production [5]. 
 
 
Figure 1.12 Use of organic solvent to prevent loss of isoprenoids from fermentation [49] 
Production of amorphadiene in cultures with and without dodecane. E. coli W3110 cultures harboring pMevT, 
pMBIS, and pADS were grown in TB in shake flasks with (■) or without (●) dodecane, and amorphadiene 
production was monitored. Data are the average concentration of three cultures. Error bars represent standard 
deviation. Culture OD600 (▲) was measured at each time point. 
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1.3 DESCRIPTION OF THE THESIS 
 
In Chapter 1, the research background and objectives of this thesis were 
described. A literature review was included, which highlights the challenges limiting 
engineering of the DXP pathway. 
 
In Chapter 2, the hypothesis was investigated whether isoprenoid production 
inhibition with overexpression of genes encoding some DXP enzymes was related to the 
changes in the transcriptions of the DXP genes, and an accurate method was established 
for transcription quantification. 
 
In Chapter 3, a novel SPE UPLC-MS method was developed, for the first time 
enabling quantification of all the DXP metabolites. Novel DXP pathway topology was 
discovered and rational approaches were designed to improve the pathway. 
 
In Chapter 4, the overlooked yet important issue was investigated whether 
overexpressed DXP enzymes formed nonfunctional insoluble aggregates in the cells. 
With the analytical tools developed in Chapter 2 and 3, the problem was confirmed and 
effectively alleviated by addition of specific osmolytes into the media. 
 
In Chapter 5, an efficient expression system was developed to control multiple 
genes’ transcription in GRAS bacterium B. subtilis. With the novel protein translation 
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optimization, the system was successfully employed to engineer the DXP pathway for the 
overproduction of amorphadiene (an isoprenoid) in B. subtilis. 
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2 TRANSCRIPTIONAL PROFILING OF 




Background: Accurate interpretation of quantitative PCR (qPCR) data requires 
normalization using constitutively expressed reference genes. Ribosomal RNA is often 
used as a reference gene for transcriptional studies in E. coli. However, the choice of 
reliable reference genes has not been systematically validated. The objective of this study 
is to identify a set of reliable reference genes for transcription analysis in recombinant 
protein over-expression studies in E. coli. 
 
Results: In this study, the meta-analysis of 240 sets of single-channel Affymetrix 
microarray data representing over-expressions of 63 distinct recombinant proteins in 
various E. coli strains identified twenty candidate reference genes that were stably 
expressed across all conditions. The expression of these twenty genes and two commonly 
used reference genes, rrsA encoding ribosomal RNA 16S and ihfB, was quantified by 
qPCR in E. coli cells over-expressing four genes of the 1-Deoxy-D-Xylulose 5-Phosphate 
pathway. From these results, two independent statistical algorithms identified three novel 
reference genes cysG, hcaT, and idnT but not rrsA and ihfB as highly invariant in two E. 
coli strains, across different growth temperatures and induction conditions. 
Transcriptomic data normalized by the geometric average of these three genes 
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demonstrated that genes of the lycopene synthetic pathway maintained steady expression 
upon enzyme overexpression. In contrast, the use of rrsA or ihfB as reference genes led 
to the mis-interpretation that lycopene pathway genes were regulated during enzyme 
over-expression. 
 
Conclusion: This study identified cysG/hcaT/idnT to be reliable novel reference 
genes for transcription analysis in recombinant protein producing E. coli. The use of 
these transcripts for normalization provides an accurate measurement of gene expression 
in metabolic engineering.  
 
2.2 SELECTION OF RELIBABLE REFERENCE GENES FOR 




Recently, transcriptomic studies using DNA microarray and qPCR identified 
gene expression changes in E. coli [21, 50, 51]. Accurate quantification of transcriptomic 
changes requires reliable normalization methods to minimize technical variations, such as 
the quality/quantity of samples and instrumental bias. To date, normalization with 
internal reference genes is the most frequently used and reliable method for qPCR data 
[52, 53]. To the best of our knowledge, there has been no systematic study to identify 
reference genes for qPCR in E. coli. To date, rrsA encoding ribosomal RNA 16S [54, 55] 
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and ihfB [51, 56-61] are the two most frequently used reference genes in E. coli. However, 
the stability of these two genes has not been validated. 
 
E. coli has been extensively used in biotechnology for the production of proteins, 
therapeutic metabolites, and biofuels [5, 50, 62]. Recombinant DNA technology has 
provided various means to express proteins with diverse functions and for the over-
production of metabolites in E. coli. As a result, a set of invariant reference genes for 
qPCR normalization during recombinant protein production is highly desired in E. coli. 
 
BL21 (DE3), a widely used E. coli strain for recombinant protein production [47], 
has been used to produce lycopene, an natural antioxidant [12]. The lycopene precursors, 
isopentenyl diphosphate (IPP) and dimethylallyl diphosphate (DMAPP), are produced via 
the DXP pathway which can be increased by the expressions of four rate limiting 
enzymes, dxs, idi, ispD, and ispF [27]. To increase lycopene production, these four 
enzymes were expressed in BL21 cells at 28°C and 37°C (Figure 2.1). The expression of 
these enzymes under non-induced condition (without IPTG induction) was found to 
increase lycopene production at 37°C (Figure 2.2). However, when expression was 
induced with IPTG induction (0.01 or 0.1 mM), lycopene production was significantly 
lower as compared to non-induced conditions. At a lower temperature (28°C), non-
induced and mild IPTG induction (0.01 mM) but not strong IPTG induction (0.1 mM) 
enhanced lycopene production. This finding is consistent with previous observations of 
the inhibitory effects of high induction on lycopene production [10, 12, 63]. In order to 
test the hypothesis that this inverse correlation of lycopene production with increasing 
induction may simply be due to the decrease in the expressions of genes involved in the 




Chapter 2: Accurate quantification of the DXP transcriptions 
lycopene pathway, we measured the transcriptional changes by qPCR. In the process of 
carrying out such measurements, we were confronted with the critical issue of selecting 
reliable reference genes for normalization of transcriptional changes. 
 
 
Figure 2.1 SDS-PAGE analysis of E. coli BL21 harboring p20T7MEP on various conditions 
Lane 1: 37°C, 4h after induction, 0mM IPTG. Lane 2: 37°C, 4h after induction, 0.01mM IPTG. Lane 3: 37°C, 
4h after induction, 0.1mM IPTG. Lane 4: 28°C, 4h after induction, 0mM IPTG. Lane 5: 28°C, 4h after 
induction, 0.01mM IPTG. Lane 6: 28°C, 4h after induction, 0.1mM IPTG. Lane 7: 37°C, 8h after induction, 
0mM IPTG. Lane 8: 37°C, 8h after induction, 0.01mM IPTG. Lane 9: 37°C, 8h after induction, 0.1mM IPTG. 
Lane 10: 28°C, 8h after induction, 0mM IPTG. Lane 11: 28°C, 8h after induction, 0.01mM IPTG. Lane 12: 
28°C, 8h after induction, 0.1mM IPTG. The arrow on the left indicates the expected size (65kDa) for dxs. All 
the cells harbor p20T7MEP and pAC-LYC.  
 
 
Figure 2.2 Time course of the production of lycopene (ppm) in E. coli BL21 harboring p20T7MEP on 
various conditions 
37°C/28°C EBI indicates the cells harboring pAC-LYC only without induction at 37°C or 28°C; 37°C/28°C 
SIDF 0mM indicates the cells harboring p20T7MEP and pAC-LYC without induction at 37°C or 28°C; 
37°C/28°C SIDF 0.01mM indicates the cells harboring p20T7MEP and pAC-LYC with 0.01mM IPTG 
induction at 37°C or 28°C; 37°C/28°C SIDF 0.1mM indicates the cells harboring p20T7MEP and pAC-LYC 
with 0.1mM IPTG induction at 37°C or 28°C; The standard errors were calculated based on four biological 
replicates 
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2.1.2 Selection of candidate reference genes from microarray 
 
A suitable reference gene should be stably expressed across all experimental 
conditions used in the study. Such reference genes are commonly identified by analyzing 
the expression stabilities of a pool of pre-selected candidate genes. However, the 
selection of such candidates poses a major challenge without a priori knowledge or 
assumptions of their stabilities. To identify suitable candidate genes, we surveyed five 
major microarray databases (Many Microbe Database M3D, NIH-GEO, Stanford 
Microarray Database, ExpressDB and Array Express) for projects pertinent to protein 
over-expression studies in E. coli. To minimize platform specific biases and variations 
caused by different data normalization strategy, only the uniformly normalized 
Affymetrix microarray data from M3D database (E_coli_v4_Build_6) were selected [64]. 
The 240 sets of microarray data from M3D database comprise over-expression studies of a 
total of 63 recombinant proteins classified into four major functional categories (Table 
2.1), providing a broad spectrum of experimental conditions in which stably expressed 
reference genes can be identified. Among the 4297 genes expressed across all arrays, the 
top fifty genes were selected based on their low coefficient of variation of signal 
intensities. These fifty genes were then further analyzed for their genetic loci and 
functional classifications [65]. Genes that belong to the same transcription unit were 
excluded and genes from diverse functional classes were selected to avoid potential 
transcriptional co-regulation. Twenty genes were short-listed as candidate reference 
genes for further analyses (Table 2.2). 
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Table 2.1 List of overexpressed genes in the selected microarray studies 
Gene Functional category (primary multi-function terms [65] or description of heterologous gene) 
b2618  ORFs -> Conserved-Hypothetical-ORFs  
bcp  cell processes -> protection -> detoxification  
CAT [heterologous gene] chloramphenicol acetyltransferase 
chpA  cell processes -> adaptations -> other (mechanical, nutritional, oxidative stress)  
cpxR  cell processes -> protection -> detoxification  
crcB  cell processes -> cell division  
crp  information transfer -> RNA related -> Transcription related  
cspF  extrachromosomal -> prophage genes and phage related functions  
dam  information transfer -> DNA related -> DNA restriction/modification  
dinl cell processes -> SOS response  
dinP cell processes -> SOS response  
dnaA information transfer -> DNA related -> DNA replication  
dnaN information transfer -> DNA related -> DNA replication  
dnaT information transfer -> DNA related -> DNA replication  
emrR  cell processes -> protection -> drug resistance/sensitivity  
era  cell processes -> cell cycle physiology  
fis information transfer -> DNA related -> DNA recombination  
fklB  information transfer -> protein related -> chaperoning, repair (refolding)  
galF  metabolism -> central intermediary metabolism -> sugar nucleotide biosynthesis, conversions  
gcvR  information transfer -> RNA related -> Transcription related  
gyrA information transfer -> DNA related -> DNA replication  
hlpA  information transfer -> protein related -> chaperoning, repair (refolding)  
holD  information transfer -> DNA related -> DNA replication  
hscA information transfer -> protein related -> chaperoning, repair (refolding)  
hscA  information transfer -> protein related -> chaperoning, repair (refolding)  
IHF information transfer -> DNA related -> DNA recombination  
lacZ  metabolism -> carbon utilization -> carbon compounds  
ldrA  cell processes -> protection -> cell killing  
lexA cell processes -> SOS response  
lon cell processes -> cell division  
mazF cell processes -> adaptations -> other (mechanical, nutritional, oxidative stress)  
mcrB  information transfer -> DNA related -> DNA degradation  
mcrC  information transfer -> DNA related -> DNA degradation  
menB metabolism -> biosynthesis of building blocks -> cofactors, small molecule carriers -> menaquinone, ubiquinone  
MGD
-1 [heterologous gene] mussel defensin protein 
minD cell processes -> cell cycle physiology  
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minE  cell processes -> cell cycle physiology  
murI cell structure -> murein  
nrdA  metabolism -> central intermediary metabolism -> nucleotide and nucleoside conversions  
nrdB metabolism -> central intermediary metabolism -> nucleotide and nucleoside conversions  
nupC  cell structure -> membrane  
PepA
A 
[heterologous gene] polypeptides which exclusively contained the 5 least abundant amino 
acids in E. coli 
PepC
O 
[heterologous gene] polypeptides which exclusively contained the 5 most abundant 
amino acids in E. coli 
pET-
3d [heterologous gene] 26 amino acids polypeptide within pET-3d backbone 
pyrC  metabolism -> biosynthesis of building blocks -> nucleotides -> pyrimidine biosynthesis  
recA cell processes -> SOS response  
relE cell processes -> protection -> cell killing  
rimI  information transfer -> protein related -> posttranslational modification  
rstB cell structure -> membrane  
ruvA cell processes -> SOS response  
ruvC  information transfer -> DNA related -> DNA recombination  
sbcB information transfer -> DNA related -> DNA replication  
sbmC  cell processes -> protection -> cell killing  
sulA cell processes -> cell division  
umuD cell processes -> SOS response  
uspA cell processes -> adaptations  
uvrA cell processes -> protection -> radiation  
yoeB  cell processes -> defense/survival  
zipA  cell processes -> cell division  
A minor fraction (4 in 63) of genes were not documented in the literature 
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intensity Primary multi-fun term 
ssrA tmRNA  13.88 cell processes -> protection -> drug resistance/sensitivity  
rnpB RnpB RNA; catalytic subunit of RNAse P 13.42 
information transfer -> RNA related -> RNA 
degradation  
pflC probable pyruvate formate lyase 2 activating enzyme 8.650 
information transfer  -> protein related  -> 
posttranslational modification  
hycG hydrogenase 3 and formate hydrogenlyase complex 8.09 
metabolism -> energy metabolism, carbon -> 
anaerobic respiration  
uxuB D-mannonate oxidoreductase  8.94 metabolism -> carbon utilization -> carbon compounds  
ygjD YgjD, target for YeaZ protease 9.74 
regulation -> type of regulation -> 
posttranscriptional -> proteases, cleavage of 
compounds  
uxuR UxuR-fructuronate  8.53 information transfer -> RNA related -> Transcription related  
yajR YajR MFS transporter 8.54 cell processes -> protection -> drug resistance/sensitivity  
asnA asparagine synthetase A  8.78 metabolism -> biosynthesis of building blocks -> amino acids -> asparagine  
hcaT  HcaT MFS transporter 8.292 cell structure  -> membrane  
ldnT  L-idonate / 5-ketogluconate / gluconate transporter 8.991 cell structure  -> membrane  
yghB conserved inner membrane protein  9.01 cell structure -> membrane  
ugpQ glycerophosphodiester phosphodiesterase, cytosolic  9.16 
metabolism -> central intermediary 
metabolism -> misc. glycerol metabolism  
metL aspartate kinase / homoserine dehydrogenase 8.973 
metabolism  -> biosynthesis of building 
blocks  -> amino acids  -> homoserine  
pbpC putative peptidoglycan enzyme 8.73 cell structure -> murein  
ilvY  IlvY DNA binding transcriptional dual regulator 9.320 
information transfer  -> RNA related  -> 
Transcription related  






metabolism  -> biosynthesis of building 
blocks  -> cofactors, small molecule carriers  
-> heme, porphyrine  
cca tRNA nucleotidyltransferase  9.19 information transfer -> RNA related -> RNA modification  
rrsA rrsA 16S ribosomal RNA 14.6 cell structure -> ribosomes  
ihfB integration host factor β subunit     
Meta-analysis of the expression profiles of 240 arrays relevant to recombinant protein production. Twenty 
candidate reference genes were selected based on the lowest CV. The log2 transformed values of the average 
signal intensities among the 240 arrays were shown as Mean. ihfB was included for comparison, and 
commonly used reference genes were highlighted. 
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2.1.3 Temporal expression of candidate reference genes in E.coli cells over-
expressing metabolic pathway genes 
 
The temporal expressions (0h, 4h & 8h after IPTG induction) of the 20 candidate 
reference genes, 2 commonly used reference genes and 7 lycopene synthetic genes were 
analyzed by qPCR (rrsA encoding ribosomal RNA 16S is both a commonly used 
reference gene and  selected gene from the meta-analysis of microarray data). All but two 
of the candidate reference genes were expressed at detectable levels in BL21 cells. The 
absolute levels of expressions of each gene were interpolated from standard curves and 
the expression levels of these genes spanned over 6 logs (Figure 2.3). All the qPCR 





Figure 2.3 Distribution of the expression levels of genes examined in E. coli BL21 (DE3) 
Box plot representation of the expression levels of seventeen candidate reference genes and two commonly 
used house-keeping genes among the 72 biological samples. The expression level of each gene was 
represented as the absolute copy number per unit input total RNA (0.0625µg), quantified by qPCR using 
serial dilutions of standards. Primer design, assay efficiency and intra- and inter-assay variations were 
reported in supplementary data (Table 2.3) 
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Table 2.3 RT-qPCR assay design and performance 









ygjD GGCAAATACCATTCGTGACAAC GCACTTAATCATCAGCGTATCG 98.29% 19.14% 35.27% 
pbpC GGAAGCCTATGGACCGAAACG CGCCGCCGAGAATGAGTG 92.62% 10.04% 29.73% 
pflC TGTGCGAAATGTTTGCGTGATG CGTTCCAGAGCGTCAAGGC 96.83% 19.37% 19.21% 
uxuB CGACGCCAGAAACCATACAGG CGCCCACTTTATCCCAATCCG 98.83% 16.56% 23.36% 
hcaT GCTGCTCGGCTTTCTCATCC CCAACCACGCTGACCAACC 95.35% 12.89% 14.58% 
ldnT CTGTTTAGCGAAGAGGAGATGC ACAAACGGCGGCGATAGC 95.69% 9.86% 16.09% 
metL TGAGCAGGATGAAGAGTCGTTG CCGTGGCTGGCGAAATCAAG 97.16% 14.09% 15.53% 
ugpQ GCCGCTACCGTTGCTTTCG GCCCGTTAATGGTCCAGTGC 97.03% 15.49% 31.54% 
ilvY GCCCATCCACGCTCTCACG CTCTTCGCCCGCTTCAGTCAG 100.20% 10.36% 16.14% 
asnA CTGGGCGGGAATTAAAGCAACC CTCCTGGCTGTGTACGAAGTGG 94.30% 9.38% 13.79% 
cca AACTGGAACACCTGACGCCTGAAC ACCTGGAAGAACACCTGTGGATTGC 100.59% 6.93% 28.82% 
yajR GCTGGGCGGCTGGATTGAC ACTGCTGACATACGGCGGTTC 94.05% 7.38% 27.14% 
uxuR TCGCCGAGTTTGCCGCTTTG GCCAGTTCACGCTCTTCCAGTTG 98.37% 9.15% 16.55% 
cysG TTGTCGGCGGTGGTGATGTC ATGCGGTGAACTGTGGAATAAACG 96.02% 14.27% 21.76% 
yghB CTGGTTAAGTGGATTGCTGTGG TTGGCAGGATCATCAGGAACG 107.02% 12.73% 16.59% 
ihfB GCGGTTTCGGCAGTTTCT CGCAGTTCTTTACCAGGTTT 93.10% 6.46% 20.61% 
rnpB CGGGCGGAGGGGAGGAAAG ATCGGCGGTTTGCTCTCTGTTG 104.47% 10.99% 28.54% 
ssrA ACGGGGATCAAGAGAGGTCAAAC CGGACGGACACGCCACTAAC 96.77% 10.84% 25.35% 
rrsA CTCTTGCCATCGGATGTGCCCA CCAGTGTGGCTGGTCATCCTCTCA 98.96% 5.39% 27.93% 
ispE GGAAGCGGTGCGAATATC ATTGCCAGAGATGATTTAATGC 100.18% 9.75% 9.36% 
ispA GCATTATTAGGTGGTAAGC ATGAGTAAGCGTGGATAC 99.00% 12.00% 33.80% 
dxr AAGGTCTGGAATACATTGAAGC CACTGCCGTCCTGATAGC 98.41% 11.01% 2.11% 
dxs AAGGCCCGCAGTTCCTGCAT GGCAAACCGCCGCTACTTTTC 93.23% 15.29% 33.84% 
ispH CTCCAACTCCAACCGTCTG CCTCTTTCACCCACTCTTCC 100.63% 10.49% 4.56% 
ispG CGCTGGTGGCTGACATCC ACGCTCTTCATTACCGATATTGC 101.10% 9.06% 9.04% 
crtE GTAAAGCGGGCGTTTCG GCCAGCAGCATCAGC 104.69% 17.08% 27.14% 
Efficiencies of amplification and inter/intra-assay precisions of the assays used to measure the twenty 
candidate reference genes, two commonly used housekeeping genes and seven target genes quantified in this 
study.  
 
2.1.4 Stabilities of candidate reference genes and common housekeeping genes 
 
Two independent statistical algorithms, geNorm and NormFinder, were used to 
analyze the gene expressions. geNorm is based on pairwise variation analysis and 
assumes none of the reference genes are co-regulated [52]. NormFinder is a model based 
method that analyzes the stability of each candidate gene, assuming all input samples are 
of equal quality and quantity [53]. The “M value” (geNorm) or “Stability Value” 
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(NormFinder) are inversely correlated to the stability of the candidate gene. The stability 
of the 17 candidate genes, rrsA and ihfB across all experimental conditions was analyzed 
by the two methods. Interestingly, both approaches identified cysG, idnT, and hcaT as the 
most stable reference genes (Figure 2.4). On the contrary, rrsA and ihfB were poorly 
ranked (Figure 2.4). In addition, pairwise variation analysis by geNorm showed that the 
combination of cysG, idnT, and hcaT is sufficiently stable (V3/4 = 0.116, less than the 
proposed cut-off of 0.15) to serve as normalizer. 
 
Further analysis of candidate gene stabilities in cells grown at different 
temperatures or at specific time point (Figure 2.5) revealed that the stability rankings of 
candidate genes do vary among different subgroups. However, cysG, idnT and hcaT were 
consistently more stable than rrsA and ihfB under all subgroups examined. The results 
suggested that the three novel candidate genes may serve as better normalizers than the 
commonly used rrsA and ihfB for gene expression profiling in BL21 cells. 
 
Figure 2.4 Stability analysis of candidate reference genes and housekeeping genes in E. coli BL21 (DE3) 
Stability rankings of the candidate reference genes, among all 72 biological samples, by geNorm (A) and 
NormFinder (B). A lower ‘Stability Value’ or ‘M-value’ correlates to higher gene expression stability.  
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Figure 2.5 Distribution of the expression levels of genes examined in sample subgroups in E. coli Bl21 
(DE3) 
Box plot representation of the expression levels of seventeen candidate reference genes and two commonly 
used house-keeping genes in subgroup 4h. The expression level of each gene was represented as the absolute 
copy number per unit input total RNA (0.0625µg), quantified by RT-qPCR using serial dilutions of standards.  
 
2.1.5 Comparison of variances of the normalization factors calculated by different 
reference gene(s) 
 
To account for sample to sample variations introduced during RNA isolation and 
quantification, raw expression profiles of target genes were scaled by a normalization 
factor (NF) calculated based on independent measurement of one or more internal 
reference genes. When multiple genes are used, NF is the geometric average of the 
relative expression level of each gene [52]. As we have previously shown [66], NF based 
on an unstable reference gene could differ significantly from the NF of a stable gene, 
which resulted in misinterpretation of normalized target gene expression. To test the 
robustness of the three novel genes in each subgroup,  the NFs computed based on cysG, 
idnT and hcaT (NFcysG/idnT/hcaT)  were compared to the NFs based on the three most stable 
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genes in each subgroup (NFtop3), e.g. cysG, ssrA and pflC (subgroup 8H).  Similarly, the 
deviations of NFrrsA and NFihfB from NFtop3 were examined. Remarkably, NFcysG/idnT/hcaT 
differed from NFtop3 by less than 40% in all subgroups examined, whereas NFrrsA deviated 
from NFtop3 by as much as 290% (Figure 2.6). Thus, the expression stabilities of cysG, 
idnT, and hcaT were sufficient to warrant their use as reference genes in each experiment 
subgroup. On the contrary, the analysis further highlighted the instability of rrsA and ihfB 
and suggested that the use of rrsA and ihfB as reference genes were likely to lead to 
significant misinterpretation of lycopene synthetic gene profile. 
 
 
Figure 2.6 Comparison of the normalization factors calculated using different reference gene(s) in E. 
coli BL21 (DE3). 
Normalization factors (NFs) calculated with idnT/cysG/hcaT, rrsA and ihfB were compared to that calculated 
by the top 3 reference genes (NFtop3)  as recommended by both NormFinder and geNorm, for each stimulus.  
The percentage deviations of NFldnT/cysG/hcaT; NFrrsA ; NFihfB from  NFtop3 (|NFx-NFtop3|/NFtop3) were 
represented by box plot. The 25th percentile to the 75th percentile (boxes), and ranges (whiskers) were shown.  
 
2.1.6 Further validation of novel reference genes in an E. coli K-12 derivative 
strain (DH10B) 
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Besides E. coli BL21 (DE3), E. coli K-12 derivatives were also frequently used 
for recombinant protein production and metabolic engineering. Unlike BL21 (DE3) 
utilizing T7 system from bacteriophage, the K-12 derivatives employ endogenous 
expression system. To test if the same set of reference genes is applicable across strains, 
the expression stabilities of the 15 candidate genes (two genes were not detectable in the 
newly tested strain as compared to BL21), rrsA and ihfB were evaluated in a K-12 
derivative, DH10B. Similar to that of BL21, DH10B cells were engineered to over-
express dxs, idi, ispD, and ispF controlled by araBAD system at 28°C. Sample 
preparation and data analysis were performed as described for BL21. 
 
When analyzed by NormFinder and geNorm, the three most stable groups of 
genes in DH10B were cysG/rrsA/pbpC and cysG/rrsA/IIcY, respectively (Table 2.4). To 
test if the use of cysG/idnT/hcaT as normalizers was still applicable, NFcysG/idnT/hcaT was 
compared with NFcysG/rrsA/pbpC in DH10B. No statistically significant difference was found 
(data not shown).  
 
Table 2.4 Stability analysis of fifteen candidate reference genes plus two commonly used house keeping 
genes in E. coli DH10B 
geNorm M-value NormFinder Stability Value 
cysG 0.563 cysG 0.210 
rrsA 0.589 pbpC 0.232 
llcY 0.59 rrsA 0.233 
pbpC 0.607 yghB 0.238 
ssrA 0.609 ygjD 0.245 
yghB 0.611 llcY 0.265 
hcaT 0.615 hcaT 0.285 
ygjD 0.615 ugpQ 0.298 
cca 0.623 ssrA 0.299 
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yajR 0.673 cca 0.303 
idnT 0.725 yajR 0.303 
ugpQ 0.74 rnpB 0.341 
pflC 0.786 pflC 0.395 
rnpB 0.792 idnT 0.399 
metL 0.793 metL 0.413 
ihfB 1.318 asn 0.708 
asn 1.337 ihfB 0.720 
Stability rankings of the fifteen candidate reference genes and two housekeeping genes, among all 15 
biological samples, by geNorm and NormFinder. A lower ‘Stability Value’ or ‘M-value’ correlates to higher 
gene expression stability.  
 
2.3 APPLICATION OF NOVEL REFERENCE GENES FOR 
TRANSCRIPTION QUANTIFICATION IN LYCOPENE 
PRODUCING E. COLI 
 
To demonstrate that the use of unstable reference genes could substantially alter 
the interpretation of target gene expression profiles, In E. coli BL21 (DE3), we examined 
the target gene profiles normalized by four NFs: NFtop3 (Normalization factors derived 
from top3 genes in each subgroup), NFcysG/idnT/hcaT, NFrrsA and NFihfB. (Figure 2.7). No 
significant difference was observed in target gene expressions normalized by 
NFcysG/idnT/hcaT or NFtop3. In both cases, lycopene synthetic genes were found to be stably 
expressed upon IPTG induction. The results showed the reduction of lycopene production 
at high induction was not due to limited transcription of lycopene synthetic genes. In 
comparison, different conclusions were derived when the results were normalized with 
rrsA or ihfB. Lycopene synthetic genes appeared to be significantly downregulated or 
upregulated when rrsA or ihfB were used as normalizers, respectively. Such 
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misinterpretation was caused by the up-regulation of rrsA and the down-regulation of 
ihfB expressions upon IPTG induction (Figure 2.8). A detailed time course analysis of rrsA 
and ihfB expression further confirmed that they were regulated during recombinant 
enzyme production. At 0.5h after IPTG induction, rrsA and ihfB were not regulated but 
the expressions were significantly altered at 2h and 4h after IPTG induction (Figure 2.9).  
 
In E. coli DH10B, The transcript levels of target gene crtE normalized by the two 
sets of reference genes were also comparable (Figure 2.10). These suggested that the 
combination of cysG/hcaT/idnT is indeed stable in DH10B cells to provide accurate 
interpretation of qPCR results. The results showed that lycopene synthetic genes were not 
transcriptionally regulated (less than 2 fold change) after induction in DH10B. Consistent 
with results in BL21, normalization with an unstable reference gene ihfB overestimated 
the upregulation of crtE transcription (Figure 2.10). Finally, it is worthy to note that 
unlike in BL21, rrsA was stably expressed in DH10B (Figure 2.10 and Table 2.4), 
suggesting that the expression systems and genetic differences among E. coli strains can 
affect the choices of qPCR reference genes. 
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Figure 2.7 Fold changes in target gene expressions normalized using different reference gene(s) in E. 
coli BL21 (DE3) 
Fold changes in transcript expressions of crtE (A), dxr (B), ispE (C), ispG (D), ispH (E) and ispA (F) in IPTG 
induced cells relative to that of control were normalized by (1) geometric mean of top three most stable genes 
in the temperature subgroup; (2) geometric mean of idnT, cysG, and hcaT; (3) rrsA or (4) ihfB. 
Normalization by rrsA falsely identified the downregulation of all target genes, and normalization by ihfB 
falsely identified the upregulation of all target genes. 2 is the threshold for upregulation and 0.5 is the 
threshold for downregulation.  
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Figure 2.8 Upregulation  of rrsA transcript expression and downregulation of ihfB transcript 
expression upon IPTG induction in E. coli BL21 (DE3) 
Fold changes in transcript expressions of rrsA (A) and ihfB (B) in IPTG induced cells relative to that of 
control were normalized by (1) geometric mean of idnT, cysG, and hcaT; (2) geometric mean of top three 




Figure 2.9 Fold change in rrsA (A), ihfB (B), and dxs (C) expression normalized to cysG/hcaT/idnT 
Fold changes in transcript expressions of rrsA (A) and ihfB (B) in IPTG induced cells relative to that of 
control were normalized by geometric mean of idnT, cysG, and hcaT. Fold changes in transcript expressions 
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of dxs (C) at 0.5h, 2h, and 4h after induction relative to that at 0h after induction normalized by geometric 
mean of idnT, cysG, and hcaT. 
 
 
Figure 2.10 Fold changes in crtE expressions normalized using different reference gene(s) in E. coli 
DH10B 
Fold changes in transcript expressions of crtE in IPTG induced cells relative to that of control were 
normalized by (1) geometric mean of top three most stable genes in E. coli DH10B – cysG/rrsA/pbpC; (2) 
geometric mean of top three most stable genes in E. coli BL21 - idnT, cysG, and hcaT; (3) rrsA or (4) ihfB. 2 




Normalization of gene expression is critical for the accurate interpretation of 
transcriptional changes determined by qPCR. The use of total RNA as a reference has 
been explored as an alternative method to normalize qPCR gene expression but this 
approach was found not to be suitable as ribosomal RNA, the main constituent, was 
found to be regulated [67-69]. The use of multiple reference genes is deemed as the 
preferred method, where technical variations are taken into account [52, 53].  In this 
study we aimed to identify reliable reference genes for qPCR in recombinant protein 
producing E. coli, since over expression of recombinant proteins in E. coli is extensively 
used in biotechnology.  
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We first analyzed single platform and uniformly normalized microarray 
expression data from a substantial number of recombinant protein over-expression studies. 
From these, we selected 20 candidate reference genes based on their variation of signal 
intensities across all selected arrays. The expression of the 20 candidate genes and 2 
commonly used reference genes were then measured by qPCR under a variety of 
conditions, including different strains, growth stages, temperatures, and induction levels. 
The expression of cysG, idnT and hcaT were found to be most constant as ranked by 
geNorm and NormFinder. Furthermore, scaling with the geometric average of these three 
genes (cysG/idnT/hcaT) provided accurate data interpretation under all tested conditions. 
The genes, idnT and hcaT, encode transporters for idonate and 3-phenylpropionate, 
respectively and cysG encodes a metabolic enzyme involved in siro-heme synthesis. 
Putative regulations of these gene expressions were predicted in EcoCyc 
(http://ecocyc.org/), but only the control of idnT expression by its substrate idonate was 
experimentally verified in E. coli [70]. Idonate is not a commonly used ingredient in E. 
coli media, which might explain the constant expression of idnT in the diverse microarray 
studies which we have analyzed and the qPCR study carried out herein.  
 
Normalization of gene expression using the scaling factor derived from the three 
most stable genes (cysG/hcaT/idnT) revealed that the induction of the 4 enzymes (dxs, idi, 
ispD, and ispF) of the DXP pathway did not inhibit the expression of the enzymes 
involved in the lycopene production. The lycopene biosynthetic genes expressed from 
multiple copy plasmid and some of endogenous DXP pathway genes were found to 
maintain constant transcription levels during high induction levels. In contrast to the 
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empirically validated reference genes described here, rrsA [54, 55] encoding ribosomal 
RNA 16S and ihfB [51, 56-61], were unvalidated but yet commonly used as reference 
genes in E. coli. Disturbingly, we found that ihfB and rrsA were less stable than 
cysG/idnT/hcaT under many conditions tested. The expression of lycopene biosynthetic 
genes normalized with ihfB appeared to be upregulated by up to 5 fold during induction, 
while rrsA overestimated gene downregulation by up to 8 fold (Figure 2.7). This type of 
incorrect interpretation can lead to faulty conclusions with regard to transcriptional 
regulations and is especially problematic in guiding further genetic manipulations. These 
results showed that the E. coli transcription machinery is fairly robust, and the lycopene 
production inhibition is not due to altered transcriptions of genes in the pathway 
examined. The results also illustrate the importance of the use of reliable, validated 
reference genes for qPCR analysis in E. coli. 
 
In addition, the stabilities of gene expressions of rrsA in two tested strains were 
not consistent. We found that rrsA expression was fairly stable in DH10B but not in 
BL21 (DE3). This could be due to the strain-specific expression systems of the two cells. 
BL21 (DE3) was engineered to produce recombinant T7 RNA polymerase for target 
protein expression whereas DH10B uses E. coli endogenous expression systems. Another 
possibility could be due to the differences in their genetic backgrounds. Nonetheless, this 
example clearly highlights the necessity of evaluating the suitability of reference genes in 
different experimental contexts. Extending the study herein, it will be of interest to 
examine the use of the normalization factor of these three genes (cysG/hcaT/idnT) in 
more specific applications including conditions in biotechnology such as heat/cold-shock 
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This systematic study included the meta-analysis of public microarray data and 
extensive in house qPCR analysis. Twenty candidate genes were identified and their 
expression stabilities were analyzed and compared with two commonly used reference 
genes rrsA and ihfB. The expression of cysG/hcaT/idnT was found to be most constant in 
the two recombinant protein producing E. coli strains across different growth stages, 
growth temperature, and inducer concentrations. Only the normalization factors derived 
from cysG/hcaT/idnT but not the ones derived from rrsA or ihfB provided accurate 
interpretation of transcriptional responses in the tested conditions. The identified 
reference genes in this study could be useful for other studies involving recombinant 




2.1.7 Bacteria strains and plasmids 
 
E. coli BL21-Gold (DE3) (Stratagen) [E. coli B F– ompT hsdS (rB– mB–) dcm+ 
Tetr gal λ(DE3) endA Hte], and DH10B (New England Biolabs) [araD139 ∆(ara,leu)7697 
fhuA lacX74 galK (ɸ80 ∆(lacZ) M15) mcrA galU recA1 endA1 nupG rpsL ∆(mrr-
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hsdRMS-mcrBC)] were used for lycopene production with pACLYC plasmid [71]. The 
dxs-idi-ispDF operon was amplified by polymerase chain reaction (PCR) from 
p20T7MEP [5]. Primers used were SacI-Ec_dxs: 
GCTTAGAGCTCAGTTTTGATATTGCCAAATA and Ec_ispF-XhoI: 
GTAACCTCGAGTCATTTTGTTGCCTTAATGA. The purified PCR product was 
ligated into a modified pBAD-B vector (Invitrogen), engineered to contain SacI & XhoI 
restriction sites. The resulting plasmid was termed pBAD-SIDF. p20T7MEP was 
transformed into BL21-Gold (DE3) and pBAD-SIDF was transformed into DH10B. 
 
2.1.8 Bacteria growth and induction of protein expression 
 
Four colonies were picked from agar plates, inoculated into 2xPY medium (20 
g/L Peptone, 10 g/L Yeast extract, and 10 g/L NaCl, pH=7) containing 34 μg/mL 
Chloramphenicol and 100 μg/mL Ampicillin, and incubated overnight. Ten micro-liter 
aliquots of overnight grown cell culture were inoculated into 1mL 2xPY medium in 
14mL BD Falcon™ tube. Cells were grown at 37°C with shaking (300rpm) till OD595 
reached the range of 0.5~1.0. The cells were then induced with various concentrations of 
L-Arabinose/IPTG and grown at 28°C or 37°C for indicated time before collected for 
RNA / protein extraction or Lycopene assay. 
 
2.1.9 Protein assay 
 
Cell suspension, equivalent to 0.5 mL OD595=1.0 cells, were withdrawn from 
each biological replicate 4 h after induction for protein assay. The cells were centrifuged 
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at 20,000 g for 1 min, and pellets were resuspended in 100 μL 2% SDS solution and 
incubated for 10 min at 95°C, The protein samples were separated on a 12% denaturing 
polyacrylamide gel and the protein bands were visualized by Instant Blue (Gentaur). 
 
2.1.10 Lycopene quantification 
 
Twenty microliters of cell suspension were sampled from each biological 
replicate at 4 h, 8 h, and 24 h after induction, and OD595 was recorded. The cells were 
centrifuged at 2,800g for 2 mins, washed twice with PBS, and resuspended in 200 μL 
acetone. Resuspended cells were vortexed for 10mins and centrifuged at 2,800g for 
2mins. One hundred microliters of supernatant was mixed with equal volume of Ethanol 
and transferred to 96 Well Optical Bottom Plates (NUNC). Lycopene content was 
determined by interpolating from a standard dilution of lycopene (Sigma), based on 
absorbance at 472nm (Spectra Max 190, Molecular Devices). Cell dry weight was 
estimated from cell density (OD595). 
 
2.1.11 Meta-analysis of microarray data 
 
Two hundred and forty sets of Affymetrix microarray expression data (RMA 
normalized) were extracted from the Many Microbe Microarray Databases (M3D 
E_coli_v4_Build_6). The data belongs to five different recombinant protein over-
expression projects (upregulation_low_norfloxacin, upregulation_high_norfloxacin, 
metabolic_burden_response, recombinant_fermenter, and stringent_response) that 
include over-expression of 63 different proteins. The mean expression value and standard 
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deviation were computed for each gene across 240 sets of microarray data. The 
coefficient of variation (CV = Standard Deviation / Mean) of signal intensity was 
calculated. The top fifty genes with the lowest CV (CV, 0.78% - 2.72%) were selected 
for further analysis of their genetic loci (ecocyc.org) and functional classifications [65]. 
 
2.1.12 Primer design 
 
The gene symbol and sequence for each candidate reference gene was retrieved 
from the affymetrix microarray probe set and compared to the NCBI E. coli BL21 (DE3) 
genomic sequence (NC_012971.1). Vector NTI Advance 10 (Invitrogen) was used to 
design two sets of primers for each target gene. The first set of primers generated 
amplicons of ~300 bp which were used as standard templates for qPCR of the targeted 
gene. The second set of primers was used for qPCR assays and was designed to amplify a 
~100 bp region within each ~300 bp template. All products generated after amplifications 
were verified by gel-electrophoresis. 
 
2.1.13 RNA purification and cDNA synthesis 
 
Total RNA from E. coli was prepared using TRIzol® reagent (Invitrogen) 
according to the manufacturer’s instructions. Total RNA was collected from samples in 
quadruplicate at each treatment time point. RNA concentration was quantified using a 
NanoDrop ND-1000 spectrophotometer (Thermo Scientific), and the 260/280 and 
260/230 ratios were examined for protein and solvent contamination. The integrities of 
all RNA samples were confirmed by formaldehyde agarose gel. Eight hundred 
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nanograms of total RNA were reverse transcribed in a total volume of 40 μL containing 
ImpromII  (Promega) for 60 min at 42°C according to the manufacturer’s instructions. 
The reaction was terminated by heating at 70°C for 5 min. 
 
2.1.14 Quantitative real-time PCR 
 
The cDNA levels were then analyzed using a Biorad iCycler 4 Real-Time PCR 
Detection System (Bio-Rad) with SYBR Green I detection. Each sample was measured in 
duplicate in a 96-well plate (Bio-rad) in a  reaction mixture (30 µL final volume) 
containing 1x XtensaMix-SG (BioWORKS), 200 nM primer mix, 2.5 mM MgCl2, 0.75 U 
of iTaq DNA polymerase (iDNA). Realtime PCR was performed with an initial 
denaturation of 3 min at 95 ºC, followed by 40 cycles of 20 s at 95 ºC, 20 s at 60 ºC, and 
20s at 72 ºC. Fluorescent detection was performed at the annealing phase and during 
subsequent dissociation curve analysis to confirm that a single product had been 
amplified. The threshold cycles (Ct) were calculated using the iQ5 Optical system 
software version 2.0. Primer dimers in all the assays showed distinct melt characteristics 
from the desired amplicons. All real-time PCR quantifications were performed 
simultaneously with PCR amplified standards and no-template controls. As PCR is an 
exponential process, it can be described by the equation, Nn = N0(1 +ε)n, where Nn is the 
number of target molecules at cycle n, N0 is the initial number of target molecules, ε is 
the efficiency of amplification and n is the number of cycles. Target amplification 
efficiency of an assay was determined from the slope of a plot of Ct (Threshold cycle) 
versus -log10 concentration of the initial number of target molecules. High efficiency of 
amplification has a slope approaching the value of 3.32 cycles (log210) for every 10-fold 
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dilution of the target. Absolute gene copy numbers for each gene were interpolated from 
standard curves. All Real-time PCR experiments were compliant with the MIQE 
(Minimum Information for Publication of Quantitative Real-Time PCR Experiments 
guidelines). 
 
2.1.15 Data analysis 
 
Data from four biological replicates were averaged for the analysis. The numbers 
of biological replicates for 4 hours, 8 hours, 28°C, 37°C subgroups were 30, 32, 29, 40.   
Gene expression stability analysis using two publicly available software tools, geNorm 
(http://medgen.ugent.be/genorm/) and NormFinder (http://www.mdl.dk/) were carried out 




The works presented in this chapter have been published in BMC molecular 
biology [72], which was featured to be ‘highly accessed’. 
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3 MASS SPECTROMETRY ANALYSIS OF 
DEOXYXYLULOSE PHOSPHATE PATHWAY 




Isoprenoids are natural products that are all derived from isopentenyl diphosphate 
(IPP) and dimethylallyl diphosphate (DMAPP). These precursors are synthesized either 
by the mevalonate (MVA) pathway or the 1-Deoxy-D-Xylulose 5-Phosphate (DXP) 
pathway. Metabolic engineering of bacteria such as E. coli and yeast has enabled 
overproduction of various isoprenoid products from the DXP pathway including lycopene, 
artemisinic acid, taxadiene and levopimaradiene. Further improvement of this pathway as 
isoprenoid product production platform will be facilitated by the ability to accurately 
measure all the metabolic intermediates of the DXP pathway simultaneously. No such 
methods have been reported to-date, thus, limiting rational pathway engineering and 
further advances in the biosynthesis of isoprenoid products. In this study, a solid phase 
extraction coupled with ultra performance liquid chromatography mass spectrometry 
(SPE UPLC-MS) method was developed for the quantification of all the DXP pathway 
intermediates simultaneously. The utility of this method was applied to measure the DXP 
intermediates in genetically engineered E. coli. Unexpectedly, methylerythritol 
cyclodiphosphate (MEC) was found to efflux when certain enzymes of the pathway were 
over-expressed, a novel competing pathway branch in the DXP metabolism. Guided by 
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these data, ispG was overexpressed which effectively reduced the efflux of MEC inside 
the cells and significantly increased isoprenoid production. The impact and mechanism of 
MEC efflux were also examined by using the developed method. This study 
demonstrated the importance of the developed tools for quantifying DXP metabolites, 
and provided new insights on rational engineering of E. coli and other bacteria for 
overproduction of isoprenoids.  
 




Engineering of the DXP pathway (also known as MEP pathway) in its 
endogenous host E. coli has been found to effectively synthesize IPP/DMAPP [5, 11]. 
Four enzymes in the DXP pathway were identified combinatorially to be rate limiting [27] 
and overexpressions of the genes encoding these enzymes were empirically optimized to 
maximize isoprenoid yields.  It is also known that excessive overexpression of these 
enzymes can inhibit isoprenoid production [5, 10, 12, 20, 63]. Recently, we tested a 
hypothesis that intense overexpression of metabolic enzymes might interfere with the 
expression of isoprenoid synthetic genes, and we found that the interference did not occur 
at least at the level of transcription [72]. To elucidate such interference, including 
metabolite inhibition, and to better understand the underlying mechanisms, one needs 
more information about the levels of DXP pathway metabolite intermediates, including 
their variation in response to genetic and environmental changes. 
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Quantification of the metabolites of the mevalonate pathway in wild type and 
engineered yeast cells allowed identification of pathway limiting steps and generated 
rational gene targets for circumventing production inhibition [73]. To date, no direct 
method to simultaneously quantify all DXP pathway intermediates (Figure 3.1) has been 
reported in biological samples. MEC was the only DXP metabolite that was previously 
detected in cell extracts, by a semi-quantitative and labor intensive method of  31P-NMR 
[74]. Thus, there has been no report of a quantitative method that can measure all the 
metabolites in the DXP pathway simultaneously. 
 
To address this need, we have developed an integrated preanalytical solid phase 
extraction (SPE) method with the use of ultra performance liquid chromatography mass 
spectrometry (UPLC-MS). UPLC-MS was first optimized with commercial and in house 
synthesized standards for all intermediates. The SPE procedure exploited the 
physiocochemical properties of the DXP intermediates to selectively enrich the target 
intermediates from biological samples. The performance of this SPE coupled UPLC-MS 
protocol was then demonstrated with synthetic standards in E. coli extracts, and was 
found to be superior in terms of sensitivity and practicability. With the developed method, 
methylerythritol cyclodiphosphate (MEC, an intermediate of the DXP pathway) was 
found to be effluxed by yet to be characterized pump systems in E. coli (Figure 3.1), 
which severely inhibited isoprenoid production. Overexpressionn of ispG was then 
explored as a rational strategy in preventing MEC efflux and increasing isoprenoid 
production. This study developed invaluable tools for future rational engineering of the 
DXP pathway for overproduction of isoprenoids. 
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Figure 3.1 Metabolites and enzymes related to the 1-Deoxy-D-xylulose 5-Phosphate pathway 
DXP: 1-deoxy-D-xylulose 5-phosphate, MEP: 2C-methyl-D-erythritol 4-phosphate, CDP-ME: 4-
diphosphocytidyl-2C-methyl D-erythritol, CDP-MEP: 4-diphosphocytidyl-2C-methyl D-erythritol 2-
phosphate, MEC: 2C-methyl-D-erythritol 2,4-diphosphate, HMBPP: hydroxylmethylbutenyl diphosphate. 
dxs: 1-deoxy-D-xylulose 5-phosphate synthase; dxr: 1-deoxy-D-xylulose 5-phosphate reductase; ispD: 4-
diphosphocytidyl-2C-methyl-D-erythritol synthase; ispE: 4-diphosphocytidyl-2-C-methylerythritol kinase; 
ispF: 2-C-methyl-D-erythritol 2,4-cyclodiphosphate synthase; ispG: 1-hydroxy-2-methyl-2-(E)-butenyl 4-
diphosphate synthase; ispH: 1-hydroxy-2-methyl-2-(E)-butenyl 4-diphosphate reductase; fosmidomycin: a 
potent dxr inhibitor [75]. 
 
3.2.2 Chemical structures of the DXP pathway intermediates 
 
In the DXP pathway (Figure 3.1), pyruvate (PYR) and glyceraldehyde 3-
phosphate (GAP) are first condensed by dxs with thiamine to produce 1-deoxy-D-
xylulose 5-phosphate (DXP) [14]. DXP is then reduced and isomerized by a single 
enzyme, dxr, with NADPH to form 2C-methyl-D-erythritol 4-phosphate (MEP) [14]. 
MEP reacts with CTP in the presence of ispD to produce 4-diphosphocytidyl-2C-methyl 
D-erythritol (CDP-ME) [14]. CDP-ME is phosphorylated by an ATP dependent kinase 
ispE to form 4-diphosphocytidyl-2C-methyl D-erythritol 2-phosphate (CDP-MEP) [14]. 
CMP is eliminated from CDP-MEP and the molecule is cyclized by ispF to form 2C-
methyl-D-erythritol 2,4-diphosphate (MEC) [14]. The ring structure of MEC is opened 
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and reduced by an iron-sulfur cluster containing enzyme ispG by a yet to be fully 
characterized mechanism to form hydroxylmethylbutenyl diphosphate (HMBPP) [18]. 
HMBPP is further reduced by another iron-sulfur cluster containing enzyme ispH to 
produce a mixture of isopentenyl diphosphate (IPP) and dimethylallyl diphosphate 
(DMAPP) [19]. Unlike the mevalonate pathway, all the DXP intermediates are 
phosphorylated and highly acidic, allowing selective purification from biological samples 
directly. The substrates (PYR and GAP) and the products (DMAPP and IPP) of the DXP 
pathway have been previously quantified [76] . However, the simultaneous quantification 
of the other DXP intermediates has yet to be reported. MEC, the product of ispF, has 
been detected by nuclear magnetic resonance (NMR) in extracts of bacteria under stress  
but the detection was not quantitative [77]. 
 
3.2.3 GC-MS analysis of the DXP pathway intermediate standards 
 
Attempts were initially made to quantify the DXP pathway intermediates by gas 
chromatography mass spectrometry (GC-MS) after derivatization with trimethylsilyl 
(TMS). The standard protocol as reported in [78] was employed in this study. DXP was 
detected at 6.70 mins with signature m/z 290, 315 and 357; MEP was detected at 6.84 
mins with signature m/z 299, 315 and 387. CDP-ME, MEC and HMBPP were not 
detected and this was likely to be due to the low volatility of the TMS derivatives, and 
thus structurally more complicated CDP-MEP was not tested. DXP and MEP were then 
serial diluted and analyzed by GC-MS. The limit of detection was at least 9 pmol per 
injection for DXP and MEP, and linearity was satisfactory (Figure 3.2). Intraday 
variation of DXP and MEP were 6.5% and 6.8% respectively at 28 pmol per injection.  
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Because GC-MS is not suitable for most of the DXP pathway intermediates, further 
characterization of this method was not carried out. 
 
 
Figure 3.2 GC-MS analysis of synthetic standard of DXP and MEP  
 
3.2.4 UPLC-MS analysis of the DXP pathway intermediate standards 
 
We next explored ultra performance liquid chromatography mass spectrometry 
(UPLC-MS) for the quantification of the DXP pathway intermediates. A time-of-fight 
mass spectrometry was selected because it has the highest scan speed and excellent mass 
accuracy as compared to other types of mass spectrometry [79]. A range of mass- to-
charge ratio (m/z) was scanned in the negative mode and 50µM standard of individual 
compound was characterized. All DXP pathway intermediates can be detected and their 
m/z were unambigously determined (Table 3.1). Separation of the DXP pathway 
intermediates was then optimized on a UPLC C18 column (1.7 µm particle size). Ion 
pairing with tributylamine allowed excellent resolutions of the various intermediates 
rapidly (10 mins per sample; Table 3.2; Figure 3.3). 
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Table 3.1 Retention time, quantification ions, linearity, limit of quantification (LOQ) and 









Linearity LOQ (µM) 
Repeatability 
(0.1µM)* 
   
Range 









DXP 5.6 213.0170±0.03 0.01 – 2 0.9934 0.01 6.85 7.71 
MEP 5.2 215.0330+0.01-0.03 0.01 – 2 0.9956 0.01 4.69 7.83 
CDP-ME 6.2 520.0730±0.03 0.01 – 0.5 0.9941 0.01 3.90 7.62 
CDP-MEP 7.3 600.0390±0.03 0.1 - 1 0.9902 0.1 10.91 11.63 
MEC 6.6 276.9884±0.03 0.02 – 2 0.9991 0.02 6.20 5.63 
HMBPP 7.0 260.9920±0.03 0.01 – 2 0.9959 0.01 6.54 9.97 
*Concentration of CDP-MEP for intra-day/inter-day variation was 0.25 µM. 
 
Table 3.2 Mobile phase gradient used for the separation of DXP intermediates in the UPLC method 
Step Time (mins) Aqueous solution* Methanol 
1 0 100% 0 
2 1.8 100% 0 
3 3.1 60% 40% 
4 4.9 60% 40% 
5 5.4 10% 90% 
6 9.5 10% 90% 
7 10 100% 0 
*Aqueous solution: 15mM acetic acid and 10mM tributylamine 
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Figure 3.3 Effects of UPLC gradient on chromatography separation of the DXP pathway intermediates 
Different concentrations (0.8, 0.4, 2.6, 2.6, 0.5 and 2 µM respectively) of DXP, MEP, CDP-ME, CDP-MEP, 
MEC, and HMBPP were prepared in 1 mL acidic extraction solution, purified by the solid phase extraction 
and quantified by the UPLC-MS method. Quantification m/z ratio for each compound was extracted from 
total ion chromatography as Table 3.1 and traces were overlaid. (A) UPLC gradient described was employed 
as Table 3.2 except 40% aqueous solution was used in step 3 and 4; (B) UPLC gradient described was 
employed as Table 3.2 except 50% aqueous solution was used in step 3 and 4; (C) UPLC gradient described 
was employed as Table 3.2; (D) UPLC gradient described was employed as Table 3.2 except 70% aqueous 
solution was used in step 3 and 4; (E) UPLC gradient described was employed as Table 3.2 except 80% 
aqueous solution was used in step 3 and 4. 
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3.2.5 Development of solid phase extraction 
 
Solid phase extraction (SPE) has been widely used to isolate analytes in various 
biological samples [80-82]. It is rapid and can enrich analytes under mild conditions 
without the need for solvent evaporation from the extracts [83]. As all the DXP 
intermediates of interest are phosphorylated (Figure 3.1), we explored the use of anion 
exchange SPE [84]. The direct SPE recoveries of all the intermediates were > 40% as 
compared to the initial concentrations of standards used (Figure 3.4). It is worthy to note 
that the LC-NH2 resin used in this study was superior in performance when compared to 
other similar supports (data not shown, [84]). 
 
To examine the linearity and limit of quantification (LOQ) of the SPE UPLC-MS 
analysis for the DXP pathway intermediates in cell extracts, mixture of DXP, MEP, CDP-
ME, CDP-MEP (in house synthesized), MEC, and HMBPP were spiked into 10mL of 
cell extracts (containing no more than 0.01 µM DXP intermediates)  to final 
concentrations ranging from 2 µM to 0.01 µM. The extracts were then loaded onto an 
SPE cartridge and eluted in ammonium hydroxide. The results showed that the final 
UPLC-MS signal of all intermediates were linearly correlated with their initial 
concentrations in cell extracts (R2>0.99). In addition, the method demonstrated the 
excellent LOQ (LOQ ≤ 0.1 µM), intraday variation and interday variations (CV < 12%), 
allowing precise quantification of the DXP pathway intermediates in biological samples 
(Table 3.1). 
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With the developed method, though LOQ of CDP-MEP (0.1 µM) was much 
higher than that of the other metabolites examined (mostly 0.01 µM), but it was still 
considerably more sensitive than reported for the quantification of mevalonate 
metabolites (a similar class of compounds to DXP metabolites) at LOQ of 4.17 µM [83]. 
CDP-MEP was found to be co-eluted with many major cellular phospho-compounds 
(such as ATP, Figure 3.5 A), which is likely to result in lower signal due to the 
phenomenon of ion suppression (Figure 3.5 B). The developed method can be further 
improved to separate CDP-MEP from ATP etc., but we did not pursue this as the 




Figure 3.4 Recoveries of the DXP pathway intermediates through solid phase extraction 
Recoveries of all the commercially available DXP pathway intermediates (DXP, MEP, CDP-ME, MEC and 
HMBPP) through the solid phase extraction were characterized. The standards were spiked into 1 mL the 
acidic extraction solution in concentration of 1 µM. The intermediates were purified from the solution and 
quantified as described. The recoveries were at least 40% for all the intermediates. Presented data were 
average of triplicates and standard errors were drawn on the plot 
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Figure 3.5 ATP co-eluted with CDP-MEP and affected its detection with the SPE UPLC-MS method 
CDP-MEP was not separated from many major cellular phosphor-compounds (such as ATP, CTP etc.) on the 
chromatography developed in this study (A). Because their high abundance, the major phosphor-compounds 
such as ATP may suppress signal of the compound co-eluted with them (known as ion-suppression [85]), 
which could cause higher LOQ of CDP-MEP in cell extracts. To test this hypothesis, various concentrations 
of ATP were spiked into the solution containing CDP-MEP, and signal of CDP-MEP by the method 
developed in this study was indeed found to be gradually decreased (B). As a control, the ATP was also 
spiked into solution with DXP, a metabolite well separated from ATP. Signal of DXP was not affected by the 
addition of ATP (B), suggesting that higher LOQ of CDP-MEP could be caused by its co-elution with other 
abundant phospho-metabolites such as ATP etc. 
 
3.3 UTILITY OF THE SPE-UPLC-MS METHOD FOR THE 
DXP PATHWAY INTERMEDIATES 
 
3.3.1 Analysis of a lycopene producing E. coli 
 
To demonstrate the utility of the method, DXP pathway intermediates were 
measured in a lycopene producing E. coli. Lycopene is an antioxidant isoprenoid and the 
production in E. coli is known to be enhanced by overexpression of four enzymes in the 
DXP pathway (dxs, idi, and ispDF) under non-induced condition [72]. Consistent with 
other studies [5, 10], the strong overexpression of the four enzymes (with 0.01mM or 
more IPTG induction) inhibited lycopene production (Figure 3.6B). In order to gain an 
insight, intracellular concentrations of the DXP pathway intermediates were quantified in 
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the cells harvested in the exponential growth phase (5h after induction). Four 
intermediates (DXP, MEP, CDP-ME and MEC, Figure 3.1) were detected in all 
treatments, and the concentrations generally increased with addition of the inducers, 
IPTG (Figure 3.6C). Among the detected intermediates, the most abundant was MEC, 
accumulation of which indicated that the metabolic flux through this pathway was not 
optimal. As demonstrated earlier [5], unbalanced flux through pathways may lead to 
inhibition of isoprenoid production in E. coli.  
 
As an abrupt decrease of intracellular MEC concentration with 0.1mM IPTG 
induction was observed, we next examined the broth to investigate whether MEC was 
released from the cells under this condition. Large quantity of MEC, more than the total 
amount found in the cellular fraction was detected in the medium (Figure 3.6D). This was 
an unexpected and intriguing as highly charged, phosphorylated compounds, are not 
known to passively diffuse across intact cell membrane. Similar growth curves were 
observed with or without 0.1mM IPTG induction (Figure 3.6A), indicative that the 
viabilities of the cells were not observably different. Therefore, the accumulation of MEC 
in broth supports the hypothesis that selective export from cells may occur through 
specific transport system/s. It is thus not unreasonable to speculate that MEC accumulates 
to an intracellular threshold concentration (~30 µmol/L Figure 3.6 C) triggering cellular 
stress response, similar to the response of the cells under heat shock/oxidative stresses 
[16]. This may then activate export transporter/s to efflux the metabolite so as to prevent 
further intracellular accumulation of MEC. This may divert carbon source away from 
biosynthesis of isoprenoid products that can result in the decrease in isoprenoid 
biosynthesis. The good inverse correlation between lycopene production and the 
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concentration of extracellular MEC at various IPTG inductions was consistent with this 
suggestion (Figure 3.7).  
 
 
Figure 3.6 Analysis of E. coli expressing DXP pathway genes 
E. coli BL21-Gold (DE3) harboring pAC-LYC and pET-SIDF was induced with IPTG at various 
concentrations and analyzed by the developed UPLC-MS method. (A) Cell growth in the first 8 hours after 
IPTG induction; (B) Lycopene at 24h after induction; (C) Intracellular DXP concentration at 5h after 
induction; (D) Extracellular MEC concentration at 5h after induction; Presented data were average of 
triplicates (except duplicates for growth curve) and standard errors were drawn on the plot.  
 
 
Figure 3.7 Correlation between lycopene production and extracellular MEC concentration 
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Lycopene production was found to be well inversely correlated with extracellular MEC concentration among 
different induction conditions. Presented data were average of triplicates and standard errors were drawn on 
the plot 
 
3.3.2 Rational engineering of the DXP pathway in E. coli for production of 
lycopene 
 
To test whether lycopene production inhibition was related by MEC efflux, the 
strain was engineered to co-overexpress ispG (with dxs-idi-ispDF), the enzyme utilizing 
MEC (Figure 3.1). In the strong induction condition (0.1mM IPTG), where lycopene 
production was severely inhibited and MEC efflux was high (Figure 3.7), co-
overexpression of ispG indeed concurrently increased lycopene production (Figure 3.8 A) 
and reduced efflux of MEC (Figure 3.8 B). Intracellular metabolites were subsequently 
quantified in an attempt to gain a better understanding of the underlying mechanisms. 
The concentration of intracellular MEC was increased with ispG overexpression, 
evidence supporting the relationship of ispG and intracellular MEC.  HMBPP (a product 
of ispG, Figure 3.1) was also readily detected inside the cells overexpressing ispG 
(HMBPP was not detectable in the parental strain expressing dxs-idi-ispDF, Figure 3.8 
D), another indication that with higher ispG more MEC was consumed for isoprenoid 
biosynthesis in this strain. All the 20 known efflux pump operons in E. coli [86] were 
analyzed at the transcription level, and the expression levels were not regulated by ispG 
overexpression (No fold change less than 0.5, Figure 3.9 A). Taken together, 
overexpression of the metabolic enzyme ispG reduced the amount of MEC efflux 
possibly by shuttling it directly to the downstream products, e.g. lycopene. 
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Figure 3.8 Overexpression of ispG to alleviate accumulation of MEC for lycopene production 
SIDF: BL21 Gold (DE3) harboring p20T7MEP and pAC-LYC; SIDFG: BL21 Gold (DE3) harboring pET-
SIDFG and pAC-LYC. (A) Lycopene production as a function of time; (B) Extracellular MEC concentration 
as a function of time; (C) Intracellular MEC concentration as a function of time; (D) Intracellular HMBPP 
concentration as a function of time. Presented data were average of triplicates and standard errors were drawn 
on the plot.  
 
 
Figure 3.9 Efflux pumps were not repressed in the strain overexpressing dxs-idi-ispDF-ispG 
Transcription fold change of efflux pump encoding genes upon ispG overexpression; bcr, mdtJ, mdtH, mdtA, 
mdtG, cmr, emrK, emrE, mdtL and acrA were known genes encoding E. coli efflux pumps. Transcriptions of 
the following efflux pump encoding genes were too low to be accurately quantified in this study: fsr, cusC, 
macA, mdtK, mdtA, mdtM and emrD. They were reported not to be expressed in aerobic conditions [86]. 
Presented data were average of triplicates and standard errors were drawn on the plot.  
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Figure 3.10 The effects of fosmidomycin inhibition of dxr on DXP metabolism 
Twenty five µg/mL fosmidomycin was applied to inhibit MEC biosynthesis at 4h after induction, and the 
metabolites of BL21 Gold (DE3) harboring pET-SIDF and pAC-LYC were analyzed before and 2h after 
inhibition; Presented data were average of triplicates and standard errors were drawn on the plot. 
 
3.3.3 Investigation of biochemical impact and mechanism of MEC efflux 
 
To further understand the impact of accumulated MEC in the media on the cell 
growth and lycopene production, synthetic MEC was spiked into the media of the E. coli 
BL21 overexpressing dxs-idi-ispDF at the uninduced condition. Lycopene production and 
growth of the cells were not significantly affected by the addition of MEC (Figure 3.11 A 
and B), suggesting that extracellular MEC does not regulate the production of lycopene. 
The concentrations of extracellular MEC at 14h after the MEC spiking were found to be 
similar to the initial spiked concentrations (Figure 3.11 B), indicative that extracellular 
MEC was not consumed by the uninduced cells. Once the cells overexpressing dxs-idi-
ispDF was induced by IPTG, significant amount of extracellular MEC was produced 
(Figure 3.6 D), which would be mixed with the spiked-in MEC and cannot be 
distinguished by the current method. Therefore, impact of extracellular MEC on the cells 
was only investigated in the uninduced conditions. In the future studies, the cells could be 
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grown on 13C carbon source, and the endogenous MEC (13C MEC) would be easily 
distinguished from the spiked-in 12C MEC, which will enable examination of impact of 
extracellular MEC in the induced cells. 
 
It was speculated based on the cell growth (Figure 3.6 A) and the chemical 
property of MEC that the metabolite was actively fluxed out via yet to be understood 
efflux pumps. To test this hypothesis, we took advantage of a recent created collection of 
single-gene deletion E. coli in Coli Genetic Stock Center (Yale University, [87]), where 
all the nonessential genes were individually knocked out in E. coli BW25113 strain. The 
collection included all the 20 known efflux pump genes [86]. The genes dxs-idi-ispDF 
were maximally overexpressed in these 20 mutants and the parental wild type strain. The 
extracellular MEC concentration of the mutant ∆fsr, ∆emrD, ∆emrE, ∆mdtA, ∆emrK, 
∆mdtM, ∆mdtH and ∆cmr was found to be much lower as compared to that of the 
parental strain (fold change less than 0.5, Figure 3.12). 
 
 
Figure 3.11 Addition of MEC does not affect production of lycopene 
Different concentrations of MEC was spiked into BL21 harboring pET-SIDF and pAC-LYC in early 
exponential growth phase (OD595=0.5~1.0). Concentrations of the spiked MEC in the media were 50 and 
100 µM, which are in the range of extracellular MEC the cells could produce upon IPTG induction (Figure 
3.6 D). The lycopene production and the extracellular MEC after cell growth were monitored. (A) Cell 
growth at 14h after the MEC spiking as a function of the spiked MEC concentration; (B) Lycopene 
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production at 24h after the MEC spiking as a function of the spiked MEC concentration; (C) The 
extracellular MEC concentration at 14h after MEC spiking 
 
 
Figure 3.12 Single knockout of the efflux pumps and MEC efflux 
There are 20 known efflux pump genes in E. coli [86], and the mutants in which each of them was single 
knocked out were available [87]. Extracellular MEC concentration of these mutants at 24h after induction 
was compared to that of their parental strain (77 ± 1.4 µM). Because final cell density of the mutants varied, 
the extracellular MEC concentration was normalized by the cell density before the comparison. AcrE mutant 
could not grow in our experiment condition.  
 
3.3.4 Analysis of bacteria other than E. coli 
 
To demonstrate the broader utility of the method developed here, measurements 
of the DXP metabolites were conducted in other bacteria. Besides E. coli, other bacteria 
have also been used for the production of isoprenoids [24]. The DXP metabolites of two 
gram negative strains (Chromobacterium violaceum [89] and Pseudomonas aeruginosa 
[90]) and two gram positive strains (Bacillus subtilis [24] and Staphylococcus aureus [91]) 
were characterized. A gram positive strain (Staphylococcus aureus [91]) that processed 
the MVA pathway but not the DXP pathway was also included as a negative control. 
Analysis of the cells harvested in the exponential growth phase (OD595= 2-3) indeed 
showed that intracellular DXP pathway intermediates can be detected in all strains except 
S. aureus (Figure 3.13). The four bacteria used in this study were all wild types, where 
the DXP pathway genes were not genetically overexpressed. The level of the DXP 
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pathway intermediates in these strains was expectedly lower than that in engineered E. 
coli, yet the developed method here has the sensitivity to measure these intermediates. 
None of the DXP pathway intermediates were detected in the broth supernatant of these 
strains (data not shown), consistent with the suggestion that the metabolic flux through 
this pathway was not limiting. 
 
 
Figure 3.13 Analysis of bacteria other than E. coli 
Intracellular DXP pathway intermediates at middle exponential growth phase. Presented data were average of 
triplicates and standard errors were drawn on the plot. C. viol. : Chromobacterium violaceum; P. aeru. : 




The engineered DXP pathway has been demonstrated to be a powerful synthetic 
scaffold for microbial production of valuable isoprenoids. However, current strategies in 
manipulation of this pathway are still mostly combinatorial in nature, which are largely 
due to the lack of methods for directly monitoring changes of the pathway in metabolite 
level. In this study, the use of UPLC-MS for the first time enabled detection of all the 
DXP metabolites. Coupling with an anion exchange solid phase extraction protocol, the 
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method was able to quantify all the DXP metabolites in biological samples with good 
sensitivity (LOQ  ≤ 0.1 µM) and reliability (intraday variation CV ≤ 11%). Since no 
quantitative analysis method has been reported for metabolic intermediates of the DXP 
pathway, the developed method was then applied for quantification of DMAPP (product 
of the DXP pathway), and the performance was compared with that in literatures. LOQ of 
DMAPP by our method was 0.01 µM (R2=0.9973 and intraday CV = 7.21%), which was 
40 times more sensitive than that of the most recent report [83] (0.01 µM vs. 0.42 µM), 
and sample preparation in our method was also rapid (5 mins) and easy (drying free), 
demonstrating the superiority of  the SPE UPLC-MS method developed in this study. In 
the analyzed biological samples, all the DXP metabolites except CDP-MEP were 
detected (Figure 3.6 C and Figure 3.8 D). A strain overexpressing dxs and ispE (the 
enzyme to produce CDP-MEP) was constructed for the purpose of demonstration of 
quantifying endogenous CDP-MEP, but it was still undetectable even in the strain, most 
probably due to the facts that ispE and ispF formed protein complex in E. coli [31] and 
consumed most CDP-MEP once it was produced. 
 
Beyond the method development, this study also significantly contributed to the 
body of knowledge on the DXP metabolism for isoprenoid production. In the engineered 
lycopene producing E. coli, MEC was found to be actively effluxed, serving as a novel 
branch in the DXP pathway. Kinetics of this competing branch pathway was estimated by 
inhibiting MEC synthesis with fosmidomycin and tracking flow of accumulated 
intracellular MEC. It was found that majority of the accumulated MEC (14.7 out of 17.5 
µmol/L, Figure 3.10) was actually effluxed within 2 hours instead of being utilized by the 
cells, indicative that MEC efflux serves as a strong competing pathway diverting carbon 
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source away from the isoprenoid biosynthesis (consistent with the inverse correlation in 
Figure 3.7). A simple calculation was also done to provide additional evidence for this 
statement; 220 µmol/L MEC accumulated in the media at 24h after induction (Figure 3.8 
B), which is equivalent to 4500 ppm lycopene and much more than the 1000 ppm 
lycopene actually produced by the same strain (Figure 3.8 A). As a rational strategy, ispG 
was then overexpressed and the efflux of MEC was successfully reduced, resulting in 
increased levels of downstream intermediates (HMBPP etc.) and production of 
isoprenoid products (lycopene). These findings have demonstrated the usefulness of the 
developed SPE UPLC-MS method. Future studies could be focused on how to more 
effectively divert the MEC efflux into isoprenoid biosynthesis, invaluable to engineering 




In this study, an anion exchange solid phase extraction was developed to 
efficiently and selectively purify all the DXP pathway intermediates from biological 
samples simultaneously. UPLC-MS (TOF) was then optimized to reliably quantify the 
purified intermediates with good sensitivity. The method allows the direct monitoring of 
DXP metabolites in cells for the production of isoprenoids, an invaluable tool for rational 
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3.6.1 Bacteria strains and plasmids 
 
E. coli BL21-Gold (DE3) (Stratagene) [E. coli B F– ompT hsdS (rB– mB–) dcm+ 
Tetr gal λ(DE3) endA Hte] was used for lycopene production with pACLYC [71]. pET-
SIDF (named as p20T7MEP in [5]) was transformed into BL21-Gold (DE3) harboring 
pACLYC. IspG was amplified by polymerase chain reaction with the extracted E. coli 
genomic DNA. Primers XhoI-RBS-ispG F and ispG-BamHI R were used (Table 3.3). 
The purified PCR product was ligated into pET-SIDF which contained XhoI and BamHI 
sites. The resulting plasmids were termed as pET-SIDFG, which was subsequently 
transformed into BL21-Gold (DE3) with pAC-LYC. 
 
E. coli DH5α (Invitrogen) [F- φ80lacZΔM15 Δ(lacZYA-argF)U169 recA1 
endA1 hsdR17(rk-, mk+) phoA supE44 thi-1 gyrA96 relA1 λ-] was used for genomic 
DNA extraction. E. coli XL10-Gold (Stratagene) [Tetr Δ(mcrA)183 Δ(mcrCB-hsdSMR-
mrr)173 endA1 supE44 thi-1 recA1 gyrA96 relA1 lac Hte [F´ proAB lacIqZΔM15 Tn10 
(Tetr) Tn5 (Kanr) Amy]] with pAC-LYC was used for production of recombinant ispE 
enzymes. ispE was amplified by polymerase chain reaction with the extracted genomic 
DNA. Primers SacI-ispE F and ispE-XhoI R were used (Table 3.3). The purified PCR 
product was ligated into a modified pBAD-B (Invitrogen) which contained a six histidine 
tag and SacI, XhoI sites. The resulting plasmids were termed as pBAD-ispE, which was 
subsequently transformed into E. coli XL10-Gold with pAC-LYC. 
 




Chapter 3: SPE UPLC-MS analysis of the DXP metabolites 
Wild type Bacillus subtilis (BGSC 1A1) was requested from BGSC. Wild type 
Chromobacterium violaceum, Pseudomonas aeruginosa and Staphylococcus aureus were 
gifts from Prof. Yew Wen Shan (Department of Biochemistry, NUS). 
 








SacI-ispE F GCTTAGAGCTCCGGACACAGTGGCCCTC 
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cysG 50F TTGTCGGCGGTGGTGATGTC 
cysG 154R ATGCGGTGAACTGTGGAATAAACG 
idnT 326F CTGTTTAGCGAAGAGGAGATGC 
idnT 410R ACAAACGGCGGCGATAGC 
hcaT 510F GCTGCTCGGCTTTCTCATCC 
hcaT 595R CCAACCACGCTGACCAACC 
 
3.6.2 Synthesis of CDP-MEP 
 
Standards of all the DXP pathway intermediates are commercially available 
(Echelon) except CDP-MEP which was synthesized in house as described in this session. 
Recombinant ispE was purified from E. coli XL10-Gold containing pBAD-ispE and 
pAC-LYC. A colony was picked from agar plate, inoculated into 2xPY medium (20 g/L 
Peptone, 10 g/L Yeast extract, and 10 g/L NaCl, pH=7) containing 34 μg/mL 
Chloramphenicol and 100 μg/mL Ampicillin, and incubated overnight. Five hundred 
microliter aliquots of overnight grown cell culture were inoculated into 25 mL 2xPY 
medium in 250 mL shake flask. Cells were grown at 37°C with shaking (300 rpm) till 
OD595 reached the range of 0.5~1.0. The cells were then induced with 10 mM L-
arabinose and grown at 20 °C for 24 hours. The cell pellets were collected and 
resuspended in 1 mL B-PER II reagent (Pierce) and homogenized on Mini-Beadbeater-16 
(Biospec) with 200 µL glass beads for 1 min. The cell lysates were centrifuged at 16,000 
g for 10 mins at 4 °C and the supernatant was diluted with 20 mL NPI-10 (50 mM 
Na2H2PO4, 300 mM NaCl, 10 mM imidazole, pH=8) and incubated with 200 mg Ni-NTA 
micro beads (USB) for 1 hour at room temperature. The beads were washed with 40 mL 
NPI-10 and eluted with 300 µL NPI-250 (50 mM Na2H2PO4, 300 mM NaCl, 250 mM 
imidazole, pH=8). 
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In a 50 µL reaction, 1.25 mM CDP-ME was converted into CDP-MEP with 10.5 
µg recombinant ispE in presence of 40 mM Tris (pH=6), 2.5 mM Mg2Cl, 50 mM β-
mercaptoethanol and 10 mM ATP. The reaction was incubated at 37 °C for 15 hours and 
terminated with 450 µL acidic extraction solution (acetonitrile/methanol/water 40:40:20 
+ 0.1 M formic acid). CDP-MEP was confirmed by mass spectrometry and the 
concentration was estimated by measuring consumed CDP-ME in the reaction. 
 
3.6.3 E. coli growth and induction of protein expression 
 
A colony was picked from agar plate, inoculated into 2xPY medium (20 g/L 
Peptone, 10 g/L Yeast extract, and 10 g/L NaCl, pH=7) containing 34 μg/mL 
Chloramphenicol and 100 μg/mL Ampicillin, and incubated overnight. Fifty microliter 
aliquots of overnight grown cell culture were inoculated into 5 mL 2xPY medium in 50 
mL Falcon tube. Cells were grown at 37 °C with shaking (300 rpm) till OD595 reached 
the range of 0.5~1.0. The cells were then induced with IPTG at indicated concentrations 
and grown at 28 °C for indicated time before collected for metabolite extraction, 
lycopene assay or transcription assay. 
 
3.6.4 Extraction and quantification of lycopene 
 
Fifty microliters of cell suspension were sampled at 24h after induction, and 
OD595 was recorded. The cells were centrifuged at 3,000g for 2 mins and resuspended in 
200 μL acetone. Resuspended cells were vortexed for 10mins and centrifuged at 3,000g 
for 2mins. One hundred microliters of supernatant was mixed with equal volume of 




Chapter 3: SPE UPLC-MS analysis of the DXP metabolites 
Ethanol and transferred to 96 Well Optical Bottom Plates (NUNC). Lycopene content 
was determined by interpolating from a standard dilution of lycopene (Sigma) based on 
absorbance at 472 nm (Spectra Max 190, Molecular Devices). 
 
3.6.5 Solid phase extraction of the DXP pathway intermediates in biological 
samples  
 
Cell suspension equivalent to 6 mL OD595=1.0 cells were withdrawn. The cells 
were centrifuged at 3,000 g for 5 mins. The cell pellets were resuspended in 10mL acidic 
extraction solution (acetonitrile/methanol/water 40:40:20 + 0.1 M formic acid) [92] for 
intracellular metabolite extraction. One hundred microliter supernatant was diluted with 
100 µL water and 800 µL modified acidic extraction solution (acetonitrile/methanol 
50:50 + 0.125 M formic acid) for extracellular metabolite extraction.  The resuspended 
cell pellets in acidic extraction solution was incubated at -20 ºC for 60 mins with periodic 
shaking. The supernatant after centrifugation was purified by loading to a cartridge 
holding 50 mg Sigma LC-NH2 resin by gravity. Diluted broth supernatant was also 
purified by LC-NH2 resin in the same way. The cartridge was eluted with 400 µL 1% 
NH4OH solution after centrifugation at 3,000 g for 2 mins and pH of eluate was 
subsequently adjusted to acidic (pH=5) by 3 µL acetic acid. 
 
3.6.6 GC-MS analysis of the DXP pathway intermediates 
 
Five microliter 2.5 mM DXP, MEP, CDP-ME, MEC and HMBPP was 
individually dried and incubated with 25 µL MOX reagent (Thermo Scientific) at 37 °C 
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for 1 hour. Twenty five microliter MSTFA + 1% TMCS (Thermo Scientific) was 
subsequently added and incubated at 37 °C for 1 hour. Samples were centrifuged at 
16,000g for 1 min and 1 µL sample containing 250 pmol metabolite was injected to GC-
MS in splitless mode at 270 °C. Agilent 7890 GC equipped with HP-5ms GC column and 
Agilent MS were used at flow rate 1 mL / min. Oven temperature was held at 100 °C for 
2mins, elevated to 300 °C at 40 °C / min and held at 300 °C for 3 mins. MS source and 
quadrupole temperature were 230 °C and 150 °C respectively. MS data was acquired in 
scan mode from 100 to 500 m/z and data analysis was done with AMDIS Chromatogram 
(NIST). 
 
3.6.7 UPLC – MS quantification of the DXP pathway intermediates 
 
A LC-MS/MS method was developed for phosphorylated sugars with HPLC 
MS/MS [76]. The method was modified for DXP intermediates with UPLC (Waters 
ACQUITY UPLC) – (TOF)MS (Bruker micrOTOF II) platform. In brief, aqueous 
solution containing 15 mM acetic acid and 10mM tributylamine and methanol were used 
as mobile phase with a UPLC C18 column (Waters CSH C18 1.7μm 2.1x 50mm). The 
elution was done at 0.15 mL/min with gradient (Table 3.2). Electrospray ionization was 
used and (TOF)MS was operated to scan 50-800 m/z in negative mode with -500V end 
plate voltage and 4500V capillary voltage. Nebulizer gas was provided in 1 bar, drying 
gas temperature was 9 mL/min, and dry gas temperature was 200 °C. Sample injection 
volume was 5 µL.  
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A range of m/z typically with 0.06 m/z width (the average m/z distribution width 
with the used MS instrument) was extracted from the acquired data (50-800 m/z) for each 
intermediate. The range of m/z was determined with 50 µM standards of each 
intermediate prepared individually in water except CDP-MEP which was in elution 
solution of SPE. At the assay condition, all the intermediates were detected in the form 
[M -H]-. Retention time was subsequently determined for each intermediate with the 
same 50 µM standards and the set m/z extraction range. The integrated area of signal 
peak at its retention time then was calculated for each intermediate with the software 
provided by the manufacturer. Based on the integrated area of signal, concentrations of 
the DXP pathway intermediates were determined by interpolating from a standard 
dilution of the intermediates prepared in biological matrix (cell extracts or broth 
supernatant).  
 
Linearity was determined with cell extracts containing DXP, MEP, CDP-ME, 
CDP-MEP, MEC and HMBPP in concentration of 2 µM, 1 µM, 0.5 µM, 0.25 µM, 0.1 
µM, 0.05 µM, 0.02 µM and 0.01 µM. Intraday/interday variations were determined with 
indicated number of replicates and sample concentration as Table 3.1. 
 
3.6.8 Transcription quantification 
 
Cell suspension equivalent to 0.1mL OD595=1.0 cells was sampled at 4h after 
induction. Gene transcription was quantified as described in [72]. Primers used were 
summarized in Table 3.3.  
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3.6.9 Fosmidomycin inhibition of MEC biosynthesis 
 
Fosmidomycin was added into the cell in the final concentration of 25 µg/mL at 
4h after the IPTG induction. Intracellular and extracellular metabolites were analyzed at 
2h after the fosmidomycin inhibition. 
 
3.6.10 Growth of bacteria other than E. coli 
 
 Glycerol stocks of Bacillus subtilis, Chromobacterium violaceum, Pseudomonas 
aeruginosa and Staphylococcus aureus were directly inoculated into 2xPY and incubated 
at 37C overnight. Cell pellets of overnight grown cells were resuspended in 10 mL 2xPY 
to cell density 0.2 (OD595) except Bacillus subtilis to cell density 0.4 (OD595) in 50 mL 





A provisional US patent (61/608,289) has been filed based on the works 
presented in this chapter. 
 
A manuscript was submitted to PLoS One. 
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4 ENHANCING SOLUBILITY OF 
DEOXYXYLULOSE PHOSPHATE PATHWAY 





Recombinant proteins are routinely overexpressed in metabolic engineering of 
microbes for production of valuable metabolites. Though it is well known that 
recombinant proteins could be expressed as inclusion bodies with no enzymatic activity, 
to date, the extent of inclusion bodies formation in metabolic engineering of microbes 
and its impact on microbial metabolite overproduction have yet to be systematically 
investigated. This study was focused on the solubility of enzymes in the deoxyxylulose 
phosphate (DXP) pathway, which is widely used for production of many isoprenoid 
pharmaceuticals. Unexpectedly, four enzymes of this pathway (dxs, ispG, ispH and ispA) 
were highly insoluble (less than 30% solubility) in all the three expression systems tested. 
Specific activity of insoluble dxs (the committed enzyme of DXP pathway) was found to 
be inactive with less than 1% of its soluble counterpart, which motivated us to design 
strategies in the attempt to improve its solubility. Expressions of fusion tagged proteins 
were not successful in most cases in producing soluble proteins. However, hypertonic 
media containing sorbitol, a chemical chaperone, successfully doubled the solubility of 
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dxs, with the concomitant improvement of microbial production of the metabolite, DXP 
(a critical metabolic intermediate for isoprenoid synthesis). Similarly, the use of sorbitol 
significantly improved the production of erg12, the committed enzyme in the mevalonate 
pathway (the other isoprenoid producing pathway). This study highlighted the negative 
impact of the formation of nonfunctional inclusion bodies in metabolic engineering, an 
often overlooked strategy. Hence, increasing the solubilities of overexpressed proteins 
offers a simple biochemical approach for the optimization of microbial isoprenoid 
production.  
 
4.2 SOLUBILITY AND ACTIVITY ANALYSIS OF THE 




Metabolic engineering of fast growing microbes has been intensively studied in 
last decade for the purpose of converting economical carbon feedstock (glycerol and 
glucose etc.) into valuable pharmaceuticals [7]. To date, gram per liter titer has been 
achieved in producing precursors of certain drugs, such as 1 g/L taxadiene produced in 
engineered E. coli [5]. Microbial metabolic engineering heavily capitalized on expression 
of recombinant proteins, which function as enzymes to catalyze biotransformations in 
vivo [10]. It is well accepted that recombinant proteins can form insoluble aggregates, 
termed as inclusion bodies [47]. Inclusion bodies are generally accepted to be 
functionally inactive and act as a stress to the host cells [93]. Hence, formation of such 
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inclusion bodies in any engineered cell factory is undoubtedly undesired. However, the 
extent to which recombinant enzymes used in metabolic engineered microbes form 
inclusion bodies to date has yet not been investigated systematically. 
 
Characterization of inclusion bodies formation in metabolic engineering should 
be carried out in a suitable model microbial system, which should have great 
commercialization potentials. Engineering of deoxyxylulose phosphate (DXP) pathway 
(also known as MEP pathway) for isoprenoid production is an ideal model system for this 
purpose. The DXP pathway exists in bacteria and produces building blocks for 
isoprenoids, a large family of chemicals comprising of more than 55,000 examples [1]. 
This pathway has been exploited in microbes to produce a variety of valuable isoprenoids, 
including taxadiene [5], artemisinic acid [7] and levopimaradiene [13] etc. These 
isoprenoids are structurally complicated and they are thus now mainly supplied by 
extracting specific plant materials, which are regenerated in a very slow rate with volatile 
market price. The metabolic engineering of the DXP pathway in microbes provides a 
promising technology for economical and sustainable production of isoprenoids. Recently, 
our group has developed a SPE UPLC-MS method to accurately quantify changes of the 
DXP pathway in metabolite level (Chapter 3), which enabled the direct evaluation of 
functional activities of all the DXP enzymes and facilitated investigation of its impacts on 
isoprenoid overproduction. 
 
This study examined the solubility status of all the DXP enzymes. Computational 
prediction was validated by empirical evaluations in E. coli. Interestingly, the soluble 
enzymes (idi, ispD and ispF) were thought to be critical when used in enhancing the 
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production of isoprenoids [27]. This study suggests that the other insoluble enzymes may 
similarly be of use but were not initially identified due to the lack of activities. Attempts 
were made to optimize the solubility of the insoluble enzymes and examine the 
enhancements in isoprenoid production. For the first time, this study highlighted 
importance of recombinant protein solubility in metabolic engineering, a fundamental 
technology in building microbial cell factory for valuable isoprenoid overproduction. 
 
4.2.2 Solubility analysis of the recombinant DXP pathway enzymes 
 
DXP pathway has so far been characterized to be a linear pathway [14], 
producing isopentenyl diphosphate (IPP) and dimethylallyl diphosphate (DMAPP) from 
pyruvate and glyceraldehyde 3-phosphate (GAP), two important metabolites in central 
metabolism (Figure 4.1). IPP and DMAPP are further assembled into farnesyl 
diphosphate (FPP), an important branching metabolic intermediate to produce C15 and 
above isoprenoids [1].  
 
Figure 4.1 Metabolites and enzymes in the DXP pathway 
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DXP: 1-deoxy-D-xylulose 5-phosphate; MEP: 2C-methyl-D-erythritol 4-phosphate; CDP-ME: 4-
diphosphocytidyl-2C-methyl D-erythritol; CDP-MEP: 4-diphosphocytidyl-2C-methyl D-erythritol 2-
phosphate; MEC: 2C-methyl-D-erythritol 2,4-diphosphate; HMBPP: (E)-4-hydroxy-3-methyl-but-2-enyl 
pyrophosphate; IPP: Isopentenyl diphosphate; DMAPP: Dimethylallyl diphosphate; FPP: Farnesyl 
diphosphate; dxs: 1-deoxy-D-xylulose 5-phosphate synthase; dxr: 1-deoxy-D-xylulose 5-phosphate reductase; 
ispD: 4-diphosphocytidyl-2C-methyl-D-erythritol synthase; ispE: 4-diphosphocytidyl-2-C-methylerythritol 
kinase; ispF: 2-C-methyl-D-erythritol 2,4-cyclodiphosphate synthase; ispG: 1-hydroxy-2-methyl-2-(E)-
butenyl 4-diphosphate synthase; ispH: 1-hydroxy-2-methyl-2-(E)-butenyl 4-diphosphate reductase; idi: 
isopentenyl diphosphate isomerase; ispA: farnesyl diphosphate synthase. 
 
Solubility of the DXP pathway proteins was first predicted based on in silico 
modeling. Substantial progresses have been made in correlating protein solubility with its 
physiochemical properties, which are largely determined by its primary sequence [94]. 
Several correlation algorithms built on published experimental data have been reported 
since 1990s [94-97]. Revised WH method [95], one of the most commonly used methods, 
was explored in this study to predict solubility of the DXP pathway proteins. A few 
proteins (dxs, ispE and ispG) were predicted by this method to be insoluble when 
overexpressed in E. coli (Table 4.1). We also took advantage of a recent comprehensive 
in vitro protein expression study, in which 3,173 E. coli proteins were produced in vitro 
and their solubilities were determined [98]. The in vitro expression study showed that a 
subgroup of the DXP pathway proteins (dxs and idi) were insoluble (Table 4.1, [98]). 
Though in silico prediction did not exactly matched the in vitro expression data, both 
results did indicate that some DXP pathway proteins might be insoluble when 
overexpressed in vivo. 
 
Table 4.1 Protein solubility predicted in silico and determined in vitro 
Protein In silico predicted solubility [95]
















*N.D.: not detected. 
 
To verify that some of the DXP enzymes when overexpressed show different 
solubilities, each of the enzymes was expressed individually in three distinct expression 
systems with different strains of E. coli (BL21 strain - T7 promoter, M15 strain - T5 
promoter and DH10B strain – araBAD promoter) at two temperatures (37 ºC and 20 ºC). 
In general, solubility of the DXP pathway proteins varied vastly among proteins ranging 
from 5% to 90% (Figure 4.2). The large variances in solubility across proteins suggested 
that the method for identifying and quantifying protein solubility is unbiased. The 
quantification method was also validated by filtration and centrifugation as shown in 
Figure 4.3. A group of the DXP enzymes (dxs, ispG, ispH and ispA) were indeed found 
to be highly insoluble (solubility less than 30% in all conditions) (Figure 4.2). Dxs, the 
committed enzyme of DXP pathway, was previously identified to be crucial (rate-limiting) 
for isoprenoid production; was found to be highly insoluble in this study. Therefore, dxs 
was chosen as a prototype of highly insoluble enzyme to study the impacts of inclusion 
bodies on metabolic engineering of E. coli for isoprenoid overproduction. 
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Figure 4.2 Solubility of DXP enzymes in E. coli 
All the enzymes in the DXP pathway were individually expressed by three expression systems (BL21 strain - 
T7 promoter (A), M15 strain - T5 promoter (B) and DH10B strain - araBAD promoter (C)) at two 
temperatures (37 °C and 20 °C). Presented data were average of triplicates and standard errors were drawn on 
the plot. The quantifications were based on image of SDS-PAGE gels, some of which (the set for DH10B 
strain – araBAD promoter, 20 °C) were demonstrated in (D). S: soluble protein fraction; IS: insoluble protein 




Figure 4.3 Validation of the protein solubility quantification method 
In this study, soluble proteins were separated from the insoluble counterparts by centrifugation at 16,000g for 
10mins. Two experiments were done to prove that the obtained soluble proteins were truly soluble. (A) The 
soluble fraction of eGFP, a demonstration protein, was loaded onto a 0.2µm filter, and its florescence before 
and after filtration was found to be statistically similar, indicating size of the eGFP in the soluble fraction to 
be less than 0.2um, an criteria of soluble protein; (B)The soluble fraction of eGFP was centrifuged for the 
prolonged time (60mins, 120mins and 180mins) at 16,000g, and its florescence did not significantly drop 
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over time, which suggested that the obtained soluble protein cannot be spun down at 16,000g, another criteria 
of soluble protein. The presented data were average of three replicates, and the standard errors were plotted. 
 
4.2.3 Activity analysis of insoluble recombinant dxs  
 
Although some inclusion bodies formed with certain enzymes were recently 
found to be active in cells [99], it is generally accepted that inclusion bodies contain 
primarily incorrect folded proteins and are functionally inactive [47]. To test whether 
insoluble dxs is catalytically functional, insoluble lysates containing recombinant dxs was 
characterized by an in vitro assay, where dxs activity was determined by measuring 
product (DXP) formation. It was found that very few DXP (less than 1 µM) was 
produced by the insoluble dxs containing lysates. As a comparison, the same amount of 
purified soluble dxs was spiked into the lysates, and high level of DXP (~700 µM) was 
then produced (Figure 4.4), confirming that specific activity of insoluble dxs was 
significantly lower than that of the soluble dxs. This observation suggested that strategies 
to increase the solubility of dxs were desirable so as to confer higher activity and 
metabolic flux towards isoprenoids in vivo.  
  
Figure 4.4 In vitro activity analysis of insoluble dxs 
Activity of insoluble dxs was compared to that of equal amount of soluble dxs by quantifying the quantity of 
DXP they produced in vitro.  (A) Quantification of the in vitro produced DXP by insoluble dxs, insoluble dxs 
+ purified dxs (soluble) and purified dxs (soluble), presented data were average of  triplicates and standard 
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errors were drawn on the plot; (B) Quantification of the insoluble dxs and the purified dxs (soluble) used in 
(A), lane 1: the cell lysate containing insoluble dxs, lane 2: protein markers, lane 3: purified soluble dxs, the 
arrowed band was dxs. 
 
4.3 IMPROVEMENT OF PROTEIN SOLUBILITY FOR 
OVERPRODUCTION OF ISOPRENOID METABOLITES  
 
4.3.1 Improvement of dxs and overproduction of deoxyxylulose phosphate 
 
Improvement of recombinant protein solubility has been intensively studied for 
the purpose of overproducing soluble proteins, and various effective strategies have been 
reported, such as lowering incubation temperature, use of fusion partner, overexpression 
of chaperone proteins and protein mutagenesis. Recently, Prasad et al. reported a simple 
yet effective approach to increase solubility of recombinant proteins, in which large 
quantity of sorbitol was added as a chemical chaperone to alleviate protein aggregation 
inside E. coli. To test whether this could increase solubility of dxs, sorbitol was added to 
the strain DH10B (Figure 4.2), and it was found that solubility of dxs was significantly 
increased by addition of 500mM sorbitol (Figure 4.5 A and B). Other chemicals were 
also explored including osmolytes (betaine [100]) and buffering agents (HEPES, 
phosphate), but solubility of dxs was not significantly improved with their additions 
(Figure 4.5 A). Beside chemical additions, dxs was also engineered at the molecular level 
for higher solubility. Four fusion partners (trxA [101], nusA [95], slyD [102] and malE 
[103]) were fused to N-terminus of dxs to enhance its solubility. Only malE fusion 
resulted in slightly increased solubility of dxs (Figure 4.6); this strategy was thus not 
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further employed given that fusion partner could offset protein specific activity and that 
the solubility of the enzyme was not significant (Figure 4.6). Cysteine residues on surface 
of dxs (C32, C330 and C457), which could form non-specific disulfide bond and cause 
protein aggregation [104], were all deactivated by mutations into alanine, but solubility of 
dxs was also not significantly increased (data not shown), suggesting insolubility of dxs 
not to be caused by disulfide bond induced aggregation. 
 
To demonstrate that improved solubility of dxs is beneficial to metabolic 
engineering of E. coli for isoprenoid production, production of DXP (committed 
metabolic intermediate in the DXP pathway) was quantified using the SPE UPLC-MS 
method developed in our lab (Chapter 3). It was found that concentrations of DXP were 
significantly higher in sorbitol treated cells than that in control cells (Figure 4.5 C). 
Addition of sorbitol could not directly alter production of DXP, because DXP 
concentration was not changed upon sorbitol addition in the strain overexpressing a 
nonfunctional dxs (Figure 4.5 C). Therefore, the elevated overproduction of DXP could 
be due to higher activity of dxs conferred by its solubility improvement. Furthermore, 
lycopene production in sorbitol treated cells was also slightly yet significantly increased 
as compared to the control cells (Figure 4.5 D), consistent with the hypothesis of elevated 
dxs activity is directly related to the increase in solubility.  
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Figure 4.5 Addition of chemicals for increasing solubility of dxs and production of isoprenoids 
(A) Effects of the chemical additions on solubility of dxs; (B) Illustration of increased protein solubility by 
sorbitol, S: soluble fraction, IS: insoluble fraction; (C) Effects of sorbitol addition on production of DXP; 
addition of sorbitol increased DXP production in the cells expressing dxs but not in the ones expressing dxs 
(R398A), a nonfunctional mutant. (D) Effects of sorbitol addition on production of lycopene;  Presented data 
were average of triplicates and standard errors were drawn on the plot. 
 
 
Figure 4.6 Effects of fusion partners on dxs solubility 
Fusion partners were cloned into N-terminus of dxs on pBAD plasmid an expressed in E. coli DH10B at 
20 °C. Fold change of dxs solubility was presented. Presented data were average of triplicates and standard 
errors were drawn on the plot. 
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4.3.2 Improvement of erg12 and overproduction of mevalonate phosphate 
 
To further confirm the importance of protein solubility in engineering of E. coli 
for isoprenoid production, a critical enzyme (erg12) in mevalonate pathway (the other 
isoprenoid precursor producing pathway, Figure 4.7 A) was examined. More than half of 
erg12 was produced in insoluble form when it was expressed in E. coli, and addition of 
sorbitol also increased its solubility significantly (Figure 4.7 B). In line with the 
hypothesis that increased solubility confers higher enzymatic activity and better 
productivity of the respective metabolite, production of mevalonate phosphate (MVAP) 
was also found to be doubled with addition of 500mM sorbitol (Figure 4.7 C). Since erg8 
and erg19 (Figure 4.7 A) are not endogenous, erg12 overexpression in E. coli produced 
and accumulated MVAP, indicative of the activity due to erg12. 
 
 
Figure 4.7 Addition of chemicals for increasing solubility of erg12 and production of mevalonate 
phosphate (MVAP) 
(A) Metabolites and enzymes in the mevalonate (MVA) pathway, MVA: Mevalonate, MVAP: Mevalonate 
phosphate, MVAPP: Mevalonate diphosphate, IPP: Isopentenyl diphosphate, DMAPP: Dimethylallyl 
diphosphate; erg12: mevalonate kinase, erg8: mevalonate phosphate kinase, erg19: mevalonate diphosphate 
decarboxylase; (B) Effects of sorbitol addition on solubility of erg12, S: soluble fraction, IS: insoluble 
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fraction; (C) Effects of sorbitol addition on production of MVAP; Since erg8 and erg19 were not present in E. 
coli and also not recombinantly expressed, MVAP accumulated in erg12 expressing E. coli, directly 





This study systematically investigated the solubility of DXP enzymes and 
examined its impacts on overproduction of important isoprenoid precursor metabolites. It 
was surprising that four out of nine enzymes in DXP pathway (dxs, ispG, ispH and ispA) 
were highly insoluble, despite the fact that these are all endogenous enzyme. Their 
insolubilities could be caused by their high expression levels (transcriptions of 
recombinant DXP RNA are ~ 1,000 fold more than those of native ones according to 
quantitative PCR [72]), which may have exceeded the capacity of the cellular protein 
folding system and thus, resulted in irreversible protein aggregation [47].  
 
This study demonstrated that the overexpression resulted in the accumulation of 
insoluble dxs, a committed yet highly insoluble enzyme in the pathway, which is non-
functional (less 1% activity than the soluble counterpart). Hence, the assumption that 
overexpression of an enzyme necessarily conferred higher enzymatic activity is unlikely 
to be true. Interestingly, the combinatorial screening study [27] based on this 
questionable assumption identified three rate-limiting DXP enzymes (idi, ispD and ispF), 
which incidentally are highly soluble, as shown in this study (Figure 4.2). It is thus not 
unreasonable to speculate that the ‘non rate-limiting’ enzymes which are found to be 
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insoluble in this study, may actually be important in the pathway if expressed in soluble 
form.  
 
Using dxs as a model enzyme, a variety of methods were explored to increase 
solubility. The addition of 500mM sorbitol was found to increase its solubility as well as 
production of the metabolic product (DXP) in E. coli, indicating the importance of 
protein solubility in isoprenoid overproduction. Similarly, erg12 was used as another 
model enzyme to verify the generality of the findings with dxs. Erg12, an enzyme in the 
mevalonate pathway was found to be significantly more soluble and showed enhanced 
MVAP production.  It is worthy to note that the use of sorbitol is acceptable as a proof-
of-concept but may not be useful for routine microbial fermentation, because very high 
concentration (500mM) of sorbitol is required which will increase cost [105]. In future, 
genetic engineering of host microbes (such as manipulation of cellular protein folding 
system [106, 107]) should be explored in detail for enhanced protein solubility, which 




In this study, four out of nine DXP proteins (dxs, ispG, ispH and ispA) were 
found to be highly insoluble when overexpressed in E. coli. Activity of insoluble dxs, the 
committed enzyme of the DXP pathway, was examined and found to be only 1% of its 
soluble counterpart. Addition of sorbitol successfully increased protein solubility of dxs 
and microbial production of its metabolic product (DXP). The strategy was also 
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applicable for erg12, a critical enzyme in mevalonate pathway. This study highlighted 





4.6.1 Bacteria strains and plasmids 
 
Bacteria strains and plasmids used in this study were summarized in Table 4.2. 
All the DXP genes were amplified from E. coli genomic DNA and cloned into the 
modified pBAD-B (Invitrogen), pET-11a (Stratagene) and pQE30 (Qiagen) plasmids 
with 6xhis tag, SacI, XhoI restriction enzyme sites. Fusion partners (trxA, nusA, malE 
and slyD) were amplified from E. coli genomic DNA and cloned into pBAD-dxs with 
NcoI and SacI sites. Erg12 was amplified from S. cerevisiae genomic DNA and cloned 
into the modified pBAD-B plasmid with 6xhis tag, SacI and XhoI restriction enzyme 
sites. All the pET-11a, pBAD-B and pQE30 based plasmids were transformed into E. coli 
BL21-Gold (DE3), E. coli DH10B and E. coli M15 respectively. pAC-LYC was co-
transformed with all the plasmids except pBAD-erg12. Primers used in this study were 
summarized in Table 4.3. 
 
Table 4.2 Bacteria strains and plasmids used in this study 
Name Description Reference 
E. coli BL21-
Gold (DE3) 
F– ompT hsdS (rB– mB–) dcm+ Tetr gal λ(DE3) endA Hte Stratagene 
E. coli DH10B araD139 Δ(ara-leu)7697 fhuA lacX74 galK (Φ80 Δ(lacZ)M15) mcrA galU 
recA1 endA1 nupG rpsL Δ(mrr-hsdRMS-mcrBC) 
NEB 
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E. coli M15 Lac, ara, gal, mtl, recA+, uvr+, [pREP4, lacI, kanr] Qiagen 
pACLYC Plasmid for production of lycopene [71] 
pET-dxs Plasmid for overexpression of dxs in E. coli BL21-Gold (DE3) This study 
pET-dxr Plasmid for overexpression of dxr in E. coli BL21-Gold (DE3) This study 
pET-ispD Plasmid for overexpression of ispD in E. coli BL21-Gold (DE3) This study 
pET-ispE Plasmid for overexpression of ispE in E. coli BL21-Gold (DE3) This study 
pET-ispF Plasmid for overexpression of ispF in E. coli BL21-Gold (DE3) This study 
pET-ispG Plasmid for overexpression of ispG in E. coli BL21-Gold (DE3) This study 
pET-ispH Plasmid for overexpression of ispH in E. coli BL21-Gold (DE3) This study 
pET-idi Plasmid for overexpression of idi in E. coli BL21-Gold (DE3) This study 
pET-ispA Plasmid for overexpression of ispA in E. coli BL21-Gold (DE3) This study 
pBAD-dxs Plasmid for overexpression of dxs in E. coli DH10B This study 
pBAD-dxr Plasmid for overexpression of dxr in E. coli DH10B This study 
pBAD-ispD Plasmid for overexpression of ispD in E. coli DH10B This study 
pBAD-ispE Plasmid for overexpression of ispE in E. coli DH10B This study 
pBAD-ispF Plasmid for overexpression of ispF in E. coli DH10B This study 
pBAD-ispG Plasmid for overexpression of ispG in E. coli DH10B This study 
pBAD-ispH Plasmid for overexpression of ispH in E. coli DH10B This study 
pBAD-idi Plasmid for overexpression of idi in E. coli DH10B This study 
pBAD-ispA Plasmid for overexpression of ispA in E. coli DH10B This study 
pQE-dxs Plasmid for overexpression of dxs in E. coli M15 This study 
pQE-dxr Plasmid for overexpression of dxr in E. coli M15 This study 
pQE-ispD Plasmid for overexpression of ispD in E. coli M15 This study 
pQE-ispE Plasmid for overexpression of ispE in E. coli M15 This study 
pQE-ispF Plasmid for overexpression of ispF in E. coli M15 This study 
pQE-ispG Plasmid for overexpression of ispG in E. coli M15 This study 
pQE-ispH Plasmid for overexpression of ispH in E. coli M15 This study 
pQE-idi Plasmid for overexpression of idi in E. coli M15 This study 
pQE-ispA Plasmid for overexpression of ispA in E. coli M15 This study 
pBAD-malE-dxs Plasmid for overexpression of malE fused dxs in E. coli DH10B This study 
pBAD-trxA-dxs Plasmid for overexpression of trxA fused dxs in E. coli DH10B This study 
pBAD-nusA-dxs Plasmid for overexpression of nusA fused dxs in E. coli DH10B This study 
pBAD-slyD-dxs Plasmid for overexpression of slyD fused dxs in E. coli DH10B This study 
pBAD-erg12 Plasmid for overexpression of erg12 in E. coli DH10B This study 
 
Table 4.3 Primers used in Chapter 4 
Name Sequence 
SacI-Ec_ispA(No ATG) GCTTAGAGCTCGACTTTCCGCAGCAACT 
Ec_ispA-XhoI GTAACCTCGAGTTATTTATTACGCTGGATGA 
SacI-Ec_ispD(No ATG) GCTTAGAGCTCGCAACCACTCATTTGGA 
Ec_ispD-XhoI GTAACCTCGAGTTATGTATTCTCCTGATGGATG 
SacI-Ec_ispE(No ATG) GCTTAGAGCTCCGGACACAGTGGCCCTC 
Ec_ispE-XhoI GTAACCTCGAGTTAAAGCATGGCTCTGTGC 
SacI-Ec_ispF(No ATG) GCTTAGAGCTCCGAATTGGACACGGTTT 
Ec_ispF-XhoI GTAACCTCGAGTCATTTTGTTGCCTTAATGA 
SacI-Ec_ispG(No ATG) GCTTAGAGCTCCATAACCAGGCTCCAAT 
Ec_ispG-XhoI GTAACCTCGAGTTATTTTTCAACCTGCTGAAC 
SacI-Ec_ispH(No ATG) GCTTAGAGCTCCAGATCCTGTTGGCCAA 
Ec_ispH-XhoI GTAACCTCGAGTTAATCGACTTCACGAATATC 
SacI-Ec_dxr(No ATG) GCTTAGAGCTCAAGCAACTCACCATTCTGGG 
Ec_dxr-XhoI GTAACCTCGAGTCAGCTTGCGAGACGC 
SacI-Ec_dxs(No ATG) GCTTAGAGCTCAGTTTTGATATTGCCAAATA 
Ec_dxs-XhoI GTAACCTCGAGTTATGCCAGCCAGGC 
SacI-Ec_idi(No ATG) GCTTAGAGCTCCAAACGGAACACGTCAT 

















4.6.2 E. coli growth and induction of protein expression 
 
A colony was picked from agar plate, inoculated into 2xPY medium (20 g/L 
Peptone, 10 g/L Yeast extract, and 10 g/L NaCl, pH=7) containing proper antibiotics, and 
incubated overnight. Ten microliter aliquots of overnight grown cell culture were 
inoculated into 1 mL 2xPY medium in 14 mL Falcon tube. Cells were grown at 37 °C 
with shaking (300 rpm) till OD595 reached the range of 0.5~1.0. The cells were then 
induced with 1mM IPTG (E. coli BL21-Gold (DE3) and E. coli M15) or 10mM L-
arabinose (E. coli DH10B) and grown at 37 °C or 20 °C for indicated time before 
collected for protein solubility assay or metabolite assay. Additives (sorbitol, betaine, 
phosphate, HEPES, mevalonate etc.) were also fed to cell culture upon induction if 
necessary. 
 
4.6.3 Prediction and quantification of protein solubility 
 
The revised WH algorithm [95] was used for prediction of protein solubility. 
Protein solubility was experimentally quantified by centrifugation as described below. At 
24h after induction, cell suspension equivalent to 1 mL OD595=1.0 cells, was centrifuged, 
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and the pellet was resuspended in 100uL B-PERII reagent (Pierce). The mixtures were 
vortexed at room temperature for 10mins, and centrifuged at 16,000g for 10mins. The 
supernatant containing soluble cell lysates, and the pellets (resuspended in 100uL 2% 
SDS) containing insoluble cell lysates were analyzed by SDS-PAGE. The SDS-PAGE 
gel was visualized by staining with instant blue (Gentaur), and image of the gel was 
processed and quantified by the software Quantity One (Bio-Rad). Protein solubility was 
defined as the quantity of the target protein in soluble cell lysates over that in total cell 
lysates (soluble cell lysates + insoluble cell lysates). Because erg12 protein cannot be 
separated from an abundant endogenous protein on SDS-PAGE, it was detected by 
western blot with anti-6xhis tag antibody (Penta-his Ab, Qiagen). 
 
4.6.4 In vitro quantification of dxs activity 
 
The DH10B strain – araBAD promoter system was used to produce dxs at 20 °C 
and characterize its catalytic activity in vitro. At 24h after induction, insoluble cell lysates 
were prepared as described above except that they were well resuspended in 100uL NPI-
10 (50 mM NaH2PO4, 300 mM NaCl, 10 mM imidazole, pH=8) instead of 2% SDS. 1uL 
the mixture was then incubated in 20uL in vitro reaction solution containing 40 mM Tris 
(pH=6), 10mM pyruvate, 20mM DL-glyceraldehyde 3-phosphate, 1mM thiamine 
diphosphate, 12.5 mM Mg2Cl, 5 mM β-mercaptoethanol. The reaction was terminated by 
1mL acidic extraction solution (acetonitrile/methanol/water 40:40:20, 100mM formic 
acid) after 2h incubation at 37 °C, and formation of DXP was quantified by SPE UPLC-
MS. 
 




Chapter 4: Insolubility of the DXP enzymes limits isoprenoid production 
4.6.5 SPE UPLC-MS quantification of DXP and MVAP 
 
Concentration of DXP and MVAP in cell culture was quantified by SPE UPLC-
MS. At 5h after induction, 50uL cell suspension was sampled and diluted in 1mL acidic 
extraction solution (acetonitrile/methanol/water 40:40:20, 100mM formic acid) and 
centrifuged at 16,000g for 1min. Supernatant was loaded to a cartridge holding 11 mg 
LC-NH2 resin (Sigma) that was activated by 200uL acidic extraction solution. The 
cartridge was centrifuged at 2,800g for 1min, and eluted with 100uL 1% NH4OH that 
was subsequently neutralized by 0.75uL acetic acid. The eluate was analyzed by UPLC 
(Waters ACQUITY UPLC) – MS (Bruker micrOTOF II) as described below.  Aqueous 
solution (A) containing 15 mM acetic acid and 10mM tributylamine and methanol (B) 
were used as mobile phase with a UPLC C18 column (Waters CSH C18 1.7μm 2.1x 
50mm). The elution was done at 0.15 mL/min with gradient (0 min 100% A, 1.8 mins 
100% A, 3.1 mins 60% A, 4.9 mins 60% A, 5.4 mins 10% A, 9.5mins 10% A, 10mins 
100% A). Electrospray ionization was used and (TOF)MS was operated to scan 50-800 
m/z in negative mode with -500V end plate voltage and 4500V capillary voltage. 
Nebulizer gas was provided in 1 bar, drying gas temperature was 9 mL/min, and dry gas 
temperature was 200 °C. Sample injection volume was 5 µL. A range of m/z was 
extracted from the acquired data for DXP (213.0170±0.03, 5.6 mins) or MVAP 
(227.0315±0.03, eluted at 6.7 mins). The integrated area of signal peak at its retention 
time then was calculated for the metabolites with the software provided by the 
manufacturer. Based on the integrated area of signal, concentration of DXP and MVAP 
were determined by interpolating from a standard dilution of the intermediates prepared 
in biological matrix. 
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4.6.6 Extraction and quantification of lycopene 
 
Fifty microliters of cell suspension were sampled at 24h after induction, and 
OD595 was recorded. The cells were centrifuged at 3,000g for 2 mins and resuspended in 
200 μL acetone. Resuspended cells were vortexed for 10mins and centrifuged at 3,000g 
for 2mins. One hundred microliters of supernatant was mixed with equal volume of 
Ethanol and transferred to 96 Well Optical Bottom Plates (NUNC). Lycopene content 
was determined by interpolating from a standard dilution of lycopene (Sigma) based on 




A manuscript was submitted to Microbial Cell Factories. 




Chapter 5: Engineering of the DXP pathway in B. subtilis 
5 ENGINEERING OF DEOXYXYLULOSE 
PHOSPHATE PATHWAY FOR ISOPRENOID 





Bacillus subtilis (B. subtilis) is a promising microbial host for production of 
pharmaceutical isoprenoids by virtue of its GRAS status by the FDA. Its fast growth rate 
and lack of codon bias for heterologous protein expression has made this an ideal 
alternative to other host (e.g, yeast). So far, engineering of B. subtilis has been limited by 
the lack of genetic tools capable of controlling multiple gene expressions. In this proof-
of-concept study, we successfully created an expression system for B. subtilis based on 
two heterologous promoters (PxylA and Pgrac) that can independently control expression 
of two gene cassettes. With the promoter system, production of amorphadiene (anti-
malaria drug precursor) was demonstrated, and 5 mg/L titer was achieved in shake flask 
conditions after rational optimization of protein translation. The achieved titer of 
amorphadiene has significantly superseded that of all the reported isoprenoid production 
in B. subtilis to date. More importantly, this study demonstrated the usefulness of the 
developed tools and strategies for metabolic engineering of B. subtilis, a potentially 
useful cell factory.  
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Escherichia coli (E. coli) is one of the most popular hosts for microbial 
production of valuable isoprenoids, because of its fast growth rate on a variety of carbon 
sources and abundant genetic manipulation tools [5, 7]. One disadvantage of this robust 
workhorse microbe is the endotoxins it produces, making it not generally considered as 
safe (GRAS) according to FDA regulations [24]. Sophisticated quality control processes 
will be required in industrial scale to monitor endotoxin levels in products of E. coli, 
especially for pharmaceutical products. Currently, most commercial companies are 
employing GRAS yeast Saccharomyces cerevisiae (S. cerevisiae) for microbial 
production of pharmaceuticals. For example, Amyris (CA, USA) produces anti-malaria 
drug artemisinin in engineered S. cerevisiae [108]. However, S. cerevisiae grows at half 
the rate as bacterium E. coli, severely limiting its isoprenoid productivity [108]. Hence, it 
is of great commercial interests to engineer a fast growing GRAS bacterium for high 
level production of pharmaceutical isoprenoids. Bacillus subtilis (B. subtilis) is a good 
candidate, because it is a GRAS bacterium with rapid growth rates [109] and has been 
widely used for production of proteins and valuable metabolites from economical carbon 
feed stocks [24, 110]. To date, most fermentations by B. subtilis only produce its 
endogenous metabolites, which usually require no or simple genetic manipulations. High 
level production of heterologous metabolites usually requires fine tuning of multiple gene 
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expressions [5], which has not been explored in B. subtilis due to relatively limited 
number of available expression tools. In this chapter, we constructed a novel expression 
system that can independently control transcription of two gene cassettes, and 
demonstrated it for the production of an artemisinin precursor (amorphadiene). Guided by 
transcriptional analysis, we also rationally improved the translation of the rate limiting 
gene by using a charged N terminus tag which resulted in enhanced production of the 
isoprenoid in B. subtilis. 
 
5.2.2 Construction of B. subtilis expression system for overproduction of 
amorphadiene 
 
Recently, promoter of Bacillus megaterium gene xylA (PxylA) was demonstrated 
to be a strong and inducible (by xylose) promoter for protein expression in B. subtilis 
[111]. If there is another controllable promoter that is compatible with PxylA in B. 
subtilis, use of the two promoters will be able to independently control expression of two 
gene cassettes. Pgrac, an IPTG inducible hybrid promoter containing an E. coli lac 
operator [112], was then selected based on the hypothesis that promoters from different 
species unlikely interfere with each other. To test the two promoter system, PxylA and 
Pgrac were employed to express the genes for synthesis of amorphadiene, a critical 
precursor of artemisinin [20]. Amorphadiene synthase (ads, Figure 5.1) was inserted after 
Pgrac on plasmid pHT01 (termed as pHT-ads), and two rate limiting genes (dxs and idi) 
in the upstream deoxyxylulose phosphate pathway (Figure 5.1) were cloned under the 
control of PxylA on plasmid pWH1520 (termed as pWH-DI) (Figure 5.2 A). 
Quantification of dxs and ads transcription showed that PxylA and Pgrac were inducible 
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by xylose and IPTG respectively when used together in B. subtilis (Figure 5.2 B). The 
transcriptions of dxs and ads were well controlled over a wide dynamic range (104 to 106 




Figure 5.1 Key metabolites and enzymes in synthesis of amorphadiene 
DXP: 1-deoxy-D-xylulose 5-phosphate; IPP: isopentenyl diphosphate; DMAPP: dimethylallyl diphosphate; 
FPP: farnesyl diphosphate; dxs: 1-deoxy-D-xylulose 5-phosphate synthase; idi: isopentenyl diphosphate 
isomerase; ads: amorphadiene synthase 
 
 
Figure 5.2 Construction of B. subtilis expression system for independent control of two gene cassettes 
(A) Illustration of Plasmid pWH-DI and Plasmid pHT-ads; (B) Quantification of transcription of genes under 
control of PxylA on pWH-DI and Pgrac on pHT-ads as a function of xylose and IPTG respectively; Presented 
data were average of four replicates and standard error of measurement was drawn. 
 
With the validated promoter system, production of amorphadiene was 
systematically optimized by fine tuning expression of the DXP genes (dxs and idi) and 
ads. Because it was feasible to explore a large search space of the expression of the two 
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gene cassettes by using different combination of xylose and IPTG, an optimal condition 
was easily identified, where ~2 mg/L amorphadiene was produced (Figure 5.3). 
Amorphadiene production increased gradually with both IPTG and xylose induction until 
0.1 mM and 0.1 % respectively (where maximal transcription levels were induced), 
suggesting that the production was strictly controlled by the availability of ads and dxs-
idi enzymes. Given that the strength of Pgrac was generally weaker than that of PxylA 
(Figure 5.2 B), it was possible that production of amorphadiene was still limited by ads 
even when transcription of it (under control of Pgrac) was maximally induced.  
  
Figure 5.3 Production of amorphadiene as a function of xylose and IPTG 
Expression system in this study employed two inducible promoters which individually controlled 
transcription of two sets of rate-limiting genes (amorphadiene synthase and two genes in the upstream DXP 
pathway). By applying different combination of inducers to tune their expression levels, production of 
amorphadiene can be conveniently and effectively optimized.  
 
5.2.3 Rational optimization of ADS translation for overproduction of 
amorphadiene 
 
Optimization of promoter is the primary strategy in manipulation of protein 
expression levels, because it largely determines efficiency of the transcription, a critical 
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step in protein production. Since there are two promoters in our system, replacement of 
Pgrac with a stronger promoter needs to re-characterize it in the presence of PxylA. So, 
expression of ads was then optimized by employing fusion of N terminus tags which 
could increase efficiency of translation, another critical step in protein production. Two 
highly charged tags, six-arginine tag (6xR, positive charge [101]) and six-aspartic acid 
tag (6xD, negative charge [101]), and one protein stabilizing tag (trxA [113]) were 
examined. Abundance of ads protein but not ads mRNA was significantly increased by 
use of the 6xR tag (Figure 5.4 A), which indicated that translation efficiency of ads was 
indeed enhanced by fusion of the 6xR tag. In line with the hypothesis that more ads could 
enhance amorphadiene production, 5 mg/L amorphadiene was produced in the cells 
expressing the 6xR tagged ads (Figure 5.4 B), which has significantly superseded the 
highest report on isoprenoid production in B. subtilis (0.5 mg isoprene / L assuming cell 
density OD595=5 and active production time of 20h).  
 
 
Figure 5.4 Poly-arginine tag improved expression of ads and increased production of amorphadiene 
Highly charged poly-arginine tags specifically enhanced translation efficiency of ads, and enhanced 
production of amorphadiene in B. subtilis. 1A1 pHT-ads: B. subtilis 1A1 harboring pHT-ads and pWH-DI; 
1A1 pHT-6xR.ads: B. subtilis 1A1 harboring pHT-6xR.ads and pWH-DI; All the cells were induced with 
maximal inductions (0.1 mM IPTG and 0.1% xylose). (A) Effects of the poly-arginine tag on transcription 
and translation of ads; the bar chart was the quantification of bs.dxs and ads/6xR.ads transcriptions, and 
transcription of ads was found to be much weaker than that of bs.dxs even at the maximal induction condition; 
the inserted graph was the western blot detection of ads and 6xR.ads, and translation of ads was significantly 
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enhanced with fusion of N terminus poly-arginine tag; (B) Effects of the poly-arginine tag on production of 




B. subtilis is an attractive microbial host for production of valuable metabolites 
from cheap feed stocks [109]. This gram positive bacterium naturally produces cellulase 
and is able to efficiently secrete the enzyme to break down extracellular cellulose into 
fermentable sugars [114]. This microbe also grows fast on both pentose and hexose, and 
is highly resistant to extreme conditions including low pH and high salts. More 
importantly, it is an extremely suitable microbe for production of highly valuable 
pharmaceutical compounds, because it is classified to be GRAS by the FDA [109]. 
However, its use for production of these heterologous therapeutic metabolites (normally 
from plants) has not been explored, probably due to the constraints in available molecular 
tools for expression of multiple genes, encoding catalytic enzymes in the product 
formation. In this study, we have enabled the simultaneous and independent control of 
two expression cassettes by creating a novel two-promoter system, and successfully 
applied it for production of amorphadiene, representing a large family of valuable 
pharmaceutical isoprenoids [1]. 
 
The only report to date on genetic engineering of B. subtilis for production of 
isoprenoids was only recently published in 2011 [24], where two genes in the upstream 
deoxyxylulose phosphate (DXP) pathway (dxs and dxr) were overexpressed to increase 
isoprene production. But the isoprene productivity after the optimization was merely 0.25 
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mg/L. Given that isoprenoid synthase is frequently rate-limiting in the production of 
isoprenoid [5, 7, 20, 115], the low isoprene titer in the study could be due to that no 
isoprene synthase was overexpressed, which motivated us to develop the novel system in 
B. subtilis capable of expressing both DXP genes and isoprenoid synthase. In the 
metabolic engineering of E. coli for isoprenoid production, dxs and idi were considered 
the most important DXP genes in the upstream [27], because dxs encodes the committed 
enzyme [23] and idi balanced the two universal isoprenoid building blocks, isopentenyl 
diphosphate and dimethylallyl diphosphate (Figure 5.1). Therefore, endogenous B. 
subtilis dxs and idi were chosen as critical enzymes in the DXP pathway subject to 
overexpression, which was subsequently confirmed to be synergistic with overexpression 
of ads (amorphadiene synthase) for enhancing amorphadiene production (Figure 5.3). 
This highlighted the importance of being able to overexpress multiple genes for valuable 
metabolite production in B. subtilis. 
 
There are few reports on improvement of protein translation for microbial 
metabolite production. In this study, we successfully employed an N terminus poly-
arginine tag to enhance translation of ads (Figure 5.4 A) and improved productivity of 
amorphadiene (Figure 5.4 B), where ads protein expression cannot be further increased 
by tuning its transcription (Figure 5.4 A). Fusion with the poly-arginine tag could change 
net charge of ads, affecting its stability in vivo [101], though detail mechanisms are yet to 
be investigated. It will be interesting to test whether the poly-arginine tag could help 
translation of other rate-limiting proteins in metabolic engineering of B. subtilis and other 
microbes for overproduction of valuable metabolites. 
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5.4 CONCLUSION  
 
This study developed a novel expression system which can independently control 
transcription of two genes in B. subtilis. The expression system enabled efficient 
optimization of B. subtilis by tuning critical genes’ expression for overproduction of 
amorphadiene, a critical metabolic intermediate in anti-malaria drug artemisinin 
biosynthesis. Besides the development of this expression system, the use of charged N 
terminus poly-arginine tag was demonstrated to be a novel and effective strategy to 
improve translation of the rate limiting enzyme ads for amorphadiene production. The 
tools developed in this study will be invaluable to engineering of B. subtilis for 




5.5.1 Bacteria strains and plasmids 
 
Escherichia coli XL10-Gold (Stratagene) [Tetr Δ(mcrA)183 Δ(mcrCB-hsdSMR-
mrr)173 endA1 supE44 thi-1 recA1 gyrA96 relA1 lac Hte [F´ proAB lacIqZΔM15 Tn10 
(Tetr) Tn5 (Kanr) Amy]] was used for genetic cloning. Bacillus subtilis 1A1 was 
requested from Bacillus Genetic Stock Center (BGSC). Amorphadiene synthase (ads) 
was synthesized (by Genescript, Figure 5.5) based on the published protein sequence 
(NCBI AAF98444) with six histidine tag at C terminus, and cloned into pHT01 
(MoBiTec), termed as pHT-ads. Variants of ads (trxA.ads, 6xR.ads, 6xD.ads) were 
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created by using the designed primers, termed as pHT-trxA.as, pHT-6xR.ads and pHT-
6xD.ads respectively. The used primers in this study were summarized in Table 5.1. The 
genes dxs and idi were amplified from B. subtilis genomic DNA, and cloned into 
pWH1520 (MoBiTec) with individual ribosome binding site, termed as pWH-DI. pWH-
DI was transformed into B. subtilis 1A1, and the pHT based plasmids were individually 





























Figure 5.5 Sequence of synthetic ads gene 
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BamHI-6xR-ADS ATAggatccATGAGACGCAGACGCAGAAGATCTCTGACTGAGGAAAAACC 
ADS-His-TGA-XbaI CGCtctagaTCAGTGATGGTGATGATGATGGATGGACATTGGGTAAACCAG 







5.5.2 Cell growth and induction of gene expression 
 
Glycerol stock of the cells was inoculated into 2xPY medium (20 g/L Peptone, 
10 g/L Yeast extract, and 10 g/L NaCl, pH=7) containing 5 μg/mL Chloramphenicol and 
15 μg/mL tetracycline, and incubated overnight. The overnight grown cell pellets were 
resuspended in 1mL 2xPY medium with the same antibiotics at cell density OD595=0.1, 
and incubated at 37C with shaking (300rpm) until cell density reached OD595=1.0. The 
cells were induced with IPTG and xylose at indicated concentrations, and incubated 28C 
with shaking (300rpm) for indicated time for transcription, protein and amorphadiene 
analysis. Two hundred microliters dodecane containing 10 mg/L caryophyllene were 
added into the cell suspensions for extraction of amorphadiene at the induction. 
 
5.5.3 Transcription analysis 
 
At 5h after induction, cell suspension equivalent to 1mL OD595=1.0 cells were 
sampled, and cell pellets were used for RNA extraction with Tri-reagent (Sigma) by 
following the manufacturer’s protocol. The RNA samples were subject to DNAse 
treatment (Promega RQ1 RNAse free DNAse) and reverse transcription (Promega 
ImProm-II) by following the manufacturer's protocol. The samples were diluted and 
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quantified by quantitative PCR as described in [72]. The primers used in this study were 
summarized in Table 5.1. 
 
5.5.4 Protein analysis 
 
At 5h after induction, cell suspension equivalent to 1mL OD595=1.0 cells were 
sampled, and cell pellets were resuspended in 100 uL 2% SDS solution and lysed by 
vortex with glass beads. Ten microliters lysates were resolved on a 12% SDS-PAGE gel, 
and subject to western blot detection with Penta-his antibody (Qiagen). 
 
5.5.5 Amorphadiene analysis 
 
At the indicated time, five microliters dodecane was sampled for amorphadiene 
quantification by gas chromatography mass spectrometry. The dodecane sample was 
diluted with ethyl acetate for 100 times, and 1 uL was injected in splitless mode. Agilent 
7890 GC equipped with HP-5ms GC column and Agilent MS were used at flow rate 1 
mL / min. Oven temperature was held at 100 °C for 0.75 mins, elevated to 170 °C at 
65 °C / min, then elevated to 300 °C at 50 °C / min and held at 300 °C for 1 min. MS 
source and quadrupole temperature were 230 °C and 150 °C respectively. Selective ion 
monitoring mode was used, and the 117, 189 and 204 m/z were recorded. Caryophyllene 
in the dodecane sample was used as internal standard, and serial diluted in vitro synthetic 
amorphadiene (manuscript in preparation) was used to construct a standard curve for 
quantification. 





6 CONCLUSION AND RECOMMENDATION OF 
FUTURE WORKS 
 
6.1 GENERAL CONCLUSION 
 
The inhibitory effects caused by protein overexpression on isoprenoid production 
were well documented in literatures but were poorly understood. In this thesis, protein 
overexpression of rate limiting genes (dxs-idi-ispDF) was found not to affect 
transcription of lycopene synthetic genes, which was previously hypothesized to trigger 
the production inhibitions. Next, protein solubility of the overexpressed DXP proteins 
was examined, and it was found that many of them (dxs, ispG, ispH and ispA) were 
highly insoluble. Addition of chemical chaperone sorbitol increased the protein solubility 
and the isoprenoid productivity, suggesting that the insolubility of the enzymes may 
contribute to the production inhibition. In the course of these studies, we have developed 
novel analytical methods for quantifying transcriptions and metabolites of the DXP 
pathway in E. coli. With these tools, we also identified a novel branch of the DXP 
pathway, the efflux of MEC, and demonstrated that overexpression of ispG could repress 
it and improve isoprenoid production. The tools developed and the knowledge generated 
in this study will be valuable to future engineering of microbes for isoprenoid production. 
 
6.2 RECOMMENDATION OF FUTURE WORKS 
 





In this thesis, solubility of the DXP pathway enzymes was demonstrated to be 
critical for increasing the flux through the pathway. It should be investigated whether this 
principle is applicable to other metabolic engineering systems. For example, it would be 
very useful if activity of downstream isoprenoid synthetic enzymes can also be improved 
by modulating their protein solubilities. 
 
The efflux of MEC was for the first time reported in this thesis and it could be 
studied in details. If the mechanisms of this process can be uncovered, effective targeted 
strategies may be designed to convert more MEC into isoprenoid synthesis processes. For 
example, transports involved in this process can be identified and genetically removed. It 
will also contribute to the body of knowledge on general E. coli cell biology. 
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